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 ABSTRACT 
 
ANTHONY C. GREGORY II 
Multiple Sclerosis Disease Distribution and Potential Impact of Environmental Air 
Pollutants in Georgia.   
Under the direction of Derek G. Shendell, D.Env, MPH 
This study’s purpose is to examine the potential relationships between MS 
(Multiple Sclerosis) and environmental outdoor air pollutants in GA (Georgia). We 
used secondary, cross-sectional data received from the member’s list of the National 
Multiples Sclerosis Society’s GA chapter (NMSS-GA), the U.S. census, and 
scorecard.org, a database based on the U.S. Environmental Protection Agency (EPA) 
Toxic Release Inventory (to 2002) and National Emissions Inventory (1999) data.  
The study population was 9,072,576 including 6,247 self-reported MS cases from 
NMSS-GA. 
 Using stepwise multivariate linear regression of census and EPA data, the best 
predictive model in GA for female or total prevalence rates used per capita income 
and coarse particles (PM-10); male prevalence rates included only per capita income.     
  The relationship between MS and PM-10 could be facilitated by influences of 
PM-10 on the systemic immune response and inflammation. More exposure and basic 
and clinical research are needed to understand environmental influences on MS. 
INDEX WORDS:  Multiple Sclerosis, Environment, Georgia, Epidemiology, Air 
Pollutants, Toxicants, Particulate Matter 
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I.  Introduction 
Background 
 Throughout time, physicians and researchers have studied thousands of 
diseases and conditions.  In that process, they have found many causes, influencing 
factors and treatments.  However, some diseases still present challenges with respect 
to determining their causes.  One of those challenges is Multiple Sclerosis (MS), a 
disease that was first identified hundreds of years ago and that affects millions of 
people across the globe.  MS is the most common demyelinating disease of the 
central nervous system. In 1992, Anderson et al (Anderson et al. 1992) estimated in 
the United States between 250,000 and 350,000 people have been affected by this 
disease.  
MS is a disease in which the body’s immune cells attack neuronal myelin 
sheaths. (Keegan and Noseworthy 2002)  In healthy individuals, these sheaths help 
the neurons to conduct messages to other neurons by covering most of the outside of 
the neuron’s axon.  This covering mediates faster neurological signals.  Due to 
continued attacks in MS, the myelin is destroyed, and, hence, the nerves are less 
efficient in conducting electrical signals.  Local inflammation may further damage the 
neuronal axons, the long extensions that help conduct electrical signals from one part 
of the neuron to the other.  The continued degeneration of the myelin may lead to 
extreme fatigue and progressively less ability to move. This process is suspected to be 
mediated largely by T-helper-1 cells (Th1).  The degeneration seen in this disease is 
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primarily diagnosed by magnetic resonance imaging (MRI); however, MRI 
specificity makes diagnosis difficult. (Fazekas et al. 1999) 
 
The Epidemiology of MS 
The epidemiology of MS is also important to consider.  In areas with higher 
MS prevalence, like Europe and North America, the prevalence of MS seems to vary 
from 60 to 200 per 100,00 population, while in lower MS areas, like Japan, these 
prevalence rates are around 6-20 per 100,000.  Of note, even though the prevalence of 
MS is lower in Asian countries, Japan has the highest prevalence of MS among Asian 
countries.  Japan is also one of the most developed countries in Asia. Thus, there are 
geographical differences in the MS distribution.  These differences are probably due 
to a variety of genetic and environmental characteristics of these areas. (Sospedra and 
Martin 2005; Sospedra et al. 2005) 
A descriptive MS study was conducted by Williamson et al. (Williamson 
2007) in 19 counties surrounding Lubbock, Texas.  This study found the prevalence 
of MS in this region per 100,000 population was 42.8 overall, 68.6 in females and 
16.6 in males.  Also, the prevalence per 100,000 population was 56.0 in non-Hispanic 
whites, 22.1 in non-Hispanic blacks, and 11.2 in Hispanics. They also reported the 
40-59 year-old age groups had the highest prevalence of MS; the 40-49 year-old 
group had 103.1 per 100,000 and the 50-59 year-old group had 119.9 per 100,000.  
(Williamson et al 2007)  In addition to this, the prevalence of MS has varied widely 
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throughout the world (Baum and Rothschild 1981; Mayer 1981) (Rosati 2001) (de la 
Maza et al. 2000), (Kurtzke 2000) 
 There seems to be little definitive information as to the etiology of MS. 
Although there are many theories about the exact role of genetics, immune cells, 
viruses, and other possible agents, there is little consensus about a single casual 
element for MS.  Thus, it is evident MS is a complex disease, and MS embodies a 
multitude of genetic and environmental factors like exposure to certain viruses, 
chemicals, and possibly environmental air pollutants subject to regulation.   
Research Questions 
 The motivation for this study comes from the knowledge of the lack of 
geographical models of MS and the lack of information as to the potential impacts of 
environmental air pollutants in MS.  With these focuses in mind, several research 
questions were created for this thesis.   
1.  What is the distribution of the prevalence of MS in GA?   
2. How does this distribution relate to census data?   
3.  How does the distribution of MS relate to environmental air pollutants?   
4. Using both environmental air pollutants and census data, what is the best predictive 
model for the MS distribution in GA? 
5.  Is there a dose-response-like relationship between the MS distribution in GA and 
specific, census selected data characteristics or environmental air pollutants?   
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II.  Literature Review  
Overview of Factors 
Many factors, both genetic and environmental, have been associated with MS 
(Hogancamp et al. 1997).  Of the genetic factors, twin studies have been instrumental. 
These studies have compared monozygotic twins (or identical twins, which have 
identical genetic information) and dizygotic twins (or paternal or non-identical twins, 
which have different genetic information) to determine if there is a significant genetic 
role for MS.  Gender-related genetic factors have also been identified.   
Aside from the genetic role, many biological factors have also been identified 
through scientific research.  This research is commonly done in animal models for 
MS as a surrogate to conducting these studies in humans.   
Environmental factors have also shown significant association with MS.  For 
example, Mayer et al. (1981) found mean annual hours of sunshine and mean annual 
temperature were protective of MS.  Conversely, infection with certain viruses 
(Keegan et al. 2002, Berti et al. 2002, (Soldan et al. 1997), distance from the equator 
(Mayer 1981), low average amount of daily sunlight (Freedman et al. 2000), lack of 
Vitamin D (Cantorna et al. 1996; Cantorna et al. 1998; Spach and Hayes 2005),  
exposure to heavy metals (Henry et al. 2007), per capita steel consumption (Mayer 
1981), number of physicians per capita (Mayer 1981), literacy rate (Mayer 1981), 
gross energy consumption, gross national product,  per capita and food consumption 
are associated with higher rates of MS  (Mayer 1981).  Among the many factors that 
may play a role in MS, viruses have been commonly cited as a common factor that 
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may influence the acquisition and progression of MS.  More details by category now 
follow. 
Genetic Factors 
 There have been several genetic clues to the etiology of MS.  Twin studies have 
been an important part in the etiology of MS, because identical twins have identical 
genetic information, while fraternal twins do not.  Twins are both the same age, and, 
assuming that they have similar environmental exposures, one can estimate the 
relative role of genetics in a disease.  In twin studies conducted for MS, a 
significantly higher prevalence of MS was found in monozygotic twins when 
compared to dizygotic twins (de Rezende and Arruda 1996; Hansen et al. 2005; 
Keegan and Noseworthy 2002).  First-degree relatives of affected people had an 
about 20 to 50-fold (2%–5%) higher risk to develop MS.  Also, concordance rates in 
monozygotic twins varied between 20% and 35% in different studies, and recent 
studies estimated the concordance rate at 25%. (Dyment et al. 2004) (Ebers et al. 
1996)  This higher prevalence of MS in monozygotic twins suggested there was a 
significant role of genetics in MS.  
The population of people affected by MS has been categorized.  Females are 
more susceptible than males (1.6:1), but this difference is evident in Relapsing 
Remitting Multiple Sclerosis (RRMS), in which the person recovers completely, but 
not in Primary Progressive Multiple Sclerosis (PPMS), in which the patient never 
completely recovers.  (Keegan and Noseworthy 2002) (Thompson et al. 1997) 
(Weinshenker 1998) 
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Aside from the higher risk of MS in women, other studies have supported the 
notion female hormones may play a role in MS.  In one of these studies, Runmarker 
and Anderson (1995) analyzed the risk of MS before, during and after pregnancy in a 
cohort of Swedish women.  They found there was a significantly decreased risk of 
MS during pregnancy.  Furthermore, they found after birth the risk did not differ 
significantly from periods when the women were not pregnant.  Also, they found 
women who have given birth had a lower risk of MS than women who had not given 
birth.  Lastly, they found a significantly lower risk of progressing from RRMS to 
PPMS in the group of women who became pregnant after the onset of MS, when 
compared to non-pregnant control patients. 
These findings suggested there may be some role of pregnancy hormones in 
MS, and other studies have also reported this same relationship.  Sicotte et al. (2002) 
found treatment of RRMS patients with estradiol (a pregnancy hormone) resulted in 
significant decreases in the number of lesions found during monthly magnetic 
resonance imaging.  This same protective effect of estradiol was seen in a later 
experiment conducted by Soldan et al. (Soldan 2003).  Both studies surmised this 
change may be due to the hormone’s effect of changing T-helper 1 immune responses 
to T-helper-2 immune responses. (NL Sicotte 2002; Soldan 2003) 
In addition to gender-roles, some racial and ethnic groups have been 
associated with generally higher rates of MS.  According to Rosati et al. (2001), MS 
was rare among Samis, Turkmen, Uzbeks, Kazakhs, Kirghizis, native Siberians, 
North and South Amerindians, Chinese, Japanese, African blacks and New Zealand 
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Maoris. Contrarily, they also saw a higher risk for MS among Sardinians, Parsis and 
Palestinians.  Also, other researchers have reported a significantly higher risk for MS 
in people of Northern European descent, although there was a lower prevalence of 
MS in New Zealand (Keegan and Noseworthy 2002).   
Biological Factors 
Scientific experiments have been used to attempt to discover more biological 
clues to the cause of MS. The animal-model of MS is known as Experimental 
Autoimmune Encephalomyelitis (EAE).  To induce EAE in mice, scientists exposed 
them to myelin basic protein, a protein similar to proteins found in myelin of most 
animals.  Thus, the immune cells will react to this protein and also to natural myelin 
surrounding murine neurons.  Catorna et al. (1996, 1998) and Spach et al. (2005) 
conducted experiments in the mouse model for Multiple Sclerosis.  
 EAE studies have been largely a part of determining the immunological basis 
for MS.  Through EAE studies, scientists determined that CD4+ T-helper 1 cells 
might be mediating this disease.  This determination was made upon realizing that 
transferring these CD4 Th1 cells could transfer EAE from an affected mouse to an 
unaffected mouse.  Transferring antibodies has not been effective for transferring 
EAE, and transferring CD8+ cells has only been effective in transferring EAE in two 
instances.   The genetic sequence of human leukocyte antigen (HLA) class II 
molecules is the strongest genetic risk for MS, and some studies also supported the 
idea that CD4 Th1 mediates MS. (Sospedra and Martin 2005; Sospedra et al. 2005) 
(Oksenberg et al. 2001)  Furthermore, there may be variation in these HLA genes, as 
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Ito et al. (Ito et al. 1998) found increased susceptibility with the western-type MS but 
not with the Japanese-type MS.  
Viruses as Biological Exposure Agents 
In addition to the EAE animal model, there is Theiler's murine 
encephalomyelitis virus model, in which a virus is deposited into susceptible mice, 
the mice develops an encephalomyelitis, and this leads to neuron and myelin 
degeneration (Dal Canto et al. 1995).   
In addition to the virus-mediated animal MS model, several authors have 
proposed viruses may cause or exacerbate MS.  Soldan and others (1997) showed that 
IgM, a common antibody for early stages of infection for Human Herpes virus 6 
(HHV-6), was increased in RRMS when compared to PPMS. They also showed 
HHV-6 serum DNA in MS patients (Soldan et al. 1997).  Berti et al. (2002) 
confirmed the presence of HHV-6 DNA in MS patients, and they stated the presence 
of HHV-6 DNA was correlated with MS progression.  These studies, together, 
suggested there may be a role of HHV-6 in MS.  In addition, the association between 
the viral DNA titers and MS progression suggested as the amount of total virus 
burden increased, there may also be increased severity of MS.  (Berti et al. 2002) 
Several other studies also lend credibility to the role of HHV-6 in the etiology 
of MS (Akhyani et al. 2000; Kong et al. 2003; Tejada-Simon et al. 2003; Virtanen et 
al. 2005).  In a previous study, Berti et al. (2000) found an increased frequency of 
HHV-6 DNA in the serum, saliva, urine, and peripheral blood lymphocytes when 
compared to controls.  Kong et al. (2003) found HHV-6 may play a role in 
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degenerating oligodendrocytes, the cells that help to nurture and create myelin.  
Tejad-Simpson et al. (2003) found 50% of T-cells were treated with HHV-6 residues 
cross-reacted with myelin basic protein.  This suggested T-cells that have seen 
foreign HHV-6 proteins may have mistakenly learned that myelin was also foreign; 
therefore, these T-cells may have mounted an immune response to neuronal myelin.  
In a study about MS and control brain tissue, Virtanen et al. (2005) found HHV-6 in 
the same place as MS lesions more often then in control brains.    
One study found HHV-6 was not related to MS.  In this study, Tuke et al. 
(2004) found there was no difference in distribution, virus type, or quantity of HHV-6 
in MS patients when compared with control patients.  
In addition to the possible role of HHV-6, Epstein Barr Virus (EBV) has also 
been associated with MS. (Hernan et al. 2001; Levin et al. 2003)  They determined 
the presence of a Epstein Barr Virus Nuclear Antigen (EBNA) was associated with an 
increased risk of MS (Hernan et al. 2001).  In a similar study, Levin et al. (2003) also 
found the risk of MS increased as the antibody titer to EBV antigens increased.  
When these authors compared the lowest EBNA titer level with the highest, they 
found the relative risk for MS was 33.9 (95% CI=4.1-283) (Levin et al. 2003; Levin 
et al. 2005).  Another researcher, Lunemann et al. (2006), found EBNA-specific 
CD4+ memory T Cells (T-helper cells) were much more common than any other type 
of EBV antigen in MS patients who were seropositive for EBV.  
Several other authors have presented studies supporting the role of EBV in the 
etiology of MS. (Cepok et al. 2005; Haahr et al. 2004; Lunemann et al. 2006; Sumaya 
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et al. 1985; Wandinger et al. 2000)  Sumaya et al. (1985) found a greater antibody 
response to EBV antigen in MS patients when compared to controls. Furthermore, 
Wandinger et al. (2000) found antibodies to EBV in 100% of all the MS patients in 
their study.  Cepok et al. (2005) found immune-cell reactivity for EBNA was much 
higher in the serum and cerebrospinal fluid of MS patients when compared with 
control patients.  Haahr et al. (2004) found a high-MS prevalence area had more than 
one third of children who were seronegative for EBV.  They also found 100% of MS 
patients in their sample were positive for EBV.  Thus, they posited EBV was 
transmitted to a large portion of the population during or after puberty in the high-MS 
prevalence area.  Finally, Wagner et al. (2004) found there was an increased risk of 
MS in people who have EBV in the serum, even after adjusting or smoking, ancestry, 
and latitude of residence.  
There seems to be some similarities between both HHV-6 and EBV.  Both 
viruses are herpes viruses, and they both replicate slowly.  Beta herpes viruses, like 
HHV-6, are known for infecting cells, and cells infected typically become larger.  
EBV, also known as Human Herpes Virus 4, is a gamma herpes virus, which is 
known for being associated with lymphocytes.  Also, gamma herpes viruses were 
found to be able to induce cell-proliferation. This is important because T-cell 
proliferation and activation usually precedes T-cell immune responses.  Also, 
proliferation and activation of other cells may lead to the characteristic inflammation 
found in many MS patients. (Hong et al. 2000; Levin et al. 2005) 
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Sunlight and Vitamin D as Physical and Chemical Agents 
Other environmental exposures like mean hours of sunshine and vitamin D 
have been associated with a lower prevalence of MS (Mayer 1981; Munger et al. 
2004)  Mayer et al. (1981) found mean annual hours of sunshine and mean annual 
temperature.  Freedman et al. studied the deaths from MS for the years of 1984 and 
1995 in 24 states of the U.S. (2000), and found a 43% decrease in MS rates amongst 
those with the highest category of sun exposure.  Through their analysis, they also 
found under high sunlight exposures black and white men and women received a 
protective effect of sunlight.  This information suggested sunlight had a significant 
physiological role that helped to mitigate MS in these two racial groups.   
Several authors supported the potential role of average incident sunlight in 
MS by showing a gradually increasing diagnosis of MS in the higher latitudes 
(Keegan et al. 2002, Mayer et al. 1981, Rosati et al. 2001).  Seasonal fluctuations may 
influence MS, with most attacks occurring in the most extreme temperatures of 
summer and winter (Ogawa et al. 2004).  Taken together, these authors suggested 
some environmental factors related to sunlight may affect MS prevalence.   
To characterize the relationship between sunlight and the incidence of MS, 
Munger et al. (2004) studied the role of vitamin D, which is primarily produced by 
the body through sunlight exposure or ingested in the form of daily vitamins.  
Through the Nurses Health Study I and II, they analyzed the role of behaviors, like 
taking daily vitamins, on the incidence of several diseases.  They found there was a 
significantly lower relative risk (RR=0.59; 95% CI=0.38 to 0.91; p for trend = 0.006) 
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for MS in women who are taking 400 IU of vitamin D per day, when compared to 
those who did not take this supplement.  They also found this relationship was not 
seen for vitamin D taken through food, and this relationship was dose dependent.  
These analyses suggested the ingested daily vitamin may have protective effects for 
MS.  The dose response suggested environmental exposure of sunlight and the dose 
of vitamin D both have effects on the incidence and prevalence of MS.   
Cantorna et al (1996) found 20 ng/day of Vitamin D completely prevented 
disability in EAE induced mice; the mice were given a calcium diet, but only the 
experimental mice were given 20 ng of vitamin D.  Also, this regimen seemed to halt 
progression of EAE after it reached the earliest stage (limp tail in mice), and when the 
vitamin D was removed, EAE progression returned to the normal level.  Cantorna et 
al (1998) further categorized the role of vitamin D in a later experiment, where they 
reported systemic and local increases in two anti-inflammatory cytokines, facilitated 
by Vitamin D, may be responsible for blocking EAE.  These experiments suggested 
that vitamin D may not only prevent Multiple Sclerosis in some cases, but also 
vitamin D may be able to halt or slow the progression of MS in mice.  Although we 
are unsure if this experiment has the same effects in humans, it provides great insight 
into the interaction between vitamin D and MS.  
In a separate EAE experiment, Spach et al. (2005) found ultraviolet-light 
exposed, vitamin D(3)-fed female mice had less clinical, histopathological and 
immunological signs of EAE than ovariectomized females or intact or castrated 
males.  They summarized this effect seemed to show synergy between vitamin D and 
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ovarian tissue with regard to EAE inhibition.  They further hypothesized an ovarian 
hormone inhibited CYP24A1 expression, which encodes a vitamin D inactivating 
enzyme, in the spinal cord, and so 1,25-dihydroxyvitamin D (vitamin D) accumulated 
and resolved the inflammation before severe EAE developed.  Lastly, they speculated 
sunlight deprivation would increase the MS risk more significantly in women than in 
men, which may contribute to the unexplained higher MS incidence in women than in 
men. (Spach and Hayes 2005)   If this study can be extrapolated to humans, it may 
suggest women may benefit more than men from taking vitamin D, and it may help to 
partially explain the higher incidence of MS in women. 
Other Environmental Factors 
Several other types of environmental exposures have been shown to be 
potentially associated with the prevalence and incidence rates of MS.  Seasonal 
fluctuations have been associated with MS in a study conducted in Japan by Ogawa et 
al. (2004).  They found optico-spinal and brain MS complications were significantly 
higher in Japan during the coldest (January and February) and hottest months (July 
and August) of the year.  They also theorized common infections occurring during the 
cold season, such as sinusitis, may play a role in these seasonal fluctuations of MS. 
(Ogawa et al. 2004) 
In another study, Edwards et al. (1998) suggested there was a relationship 
between infections and MS exacerbations.  They reported a twofold increase in MS 
exacerbations (p=0.004, OR 2.0, CI 1.3–3.2) during symptomatic upper respiratory 
track infections that lasted more than 24 hours when compared to periods without 
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symptomatic upper respiratory tract infections.  Thus, these researchers found upper 
respiratory tract infections, which may be caused by viruses, may also affect the 
frequency of MS symptoms.   
 Henry et al. (2007) analyzed MS in cohorts based in two Texas schools.  They 
reported 22 of the women in their study had MS, and they found a crude prevalence 
estimate of 411 per 100,000 population.   Also, they established three of the 22 
women, who had childhood hair samples collected and archived to test for heavy 
metals exposure, had elevated levels of lead and mercury in their childhood hair.  
Several authors have also proposed a potential role of heavy metals in new clusters of 
MS cases (Ingalls 1986) (Landrigan et al. 1975). In addition to this, Williamson and 
Henry (2004) acknowledged there has been community concern over the possible role 
of toxins from hazardous waste sites in new cases of MS.    
Few studies have focused on the roles of environmental air in the incidence 
and progression of MS.  One study on this subject was conducted in Finland by 
Oikonen et al. (2003).  In this study, the role of ambient air quality was found to be 
associated with MS prevalence.  In this study, the researchers found MS relapse was 
associated with PM-10 concentrations in southern Finland. They found there was a 
strong interaction between PM-10, CO and acidic gases (NOx and SO2).  Thus, they 
used multivariate logistic regression to attempt to differentiate the roles of acidic 
gases and the roles of PM-10 from each other.  They found the odds of relapse was 
4.143 (p<0.001) following a one-month lag after peak levels of PM-10.  They also 
found an even larger odds ratio for acidic gases one month after peak levels 
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(OR=9.285, 95% CI=2.744, 31.418).  These results, however, must be interpreted 
with caution due to small sample sizes and crude exposure estimates. 
Also, another study found that environmental exposure to radon may be a 
contributory factor in MS.  In this study, Bolviken et al (Bolviken et al. 2003) 
assessed the correlation between radon exposure and MS, and they found a positive 
correlation (p< 0.01).  They surmised that Radon inhaled in air maybe contributory 
factor to MS.   
These data suggested that MS relapse may be associated with high rates of 
environmental air pollutants in Finland.  With this in mind, the purpose of this study 
will be to assess the suspected role of environmental air pollutants in MS, using data 
on source emissions and MS in the state of Georgia by county.  
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III.   Methods 
The GSU Institutional Review Board (IRB) approved this study in February 
2007 (approved protocol # H07341).  To receive approval, the methodology and 
supporting documents were submitted to GSU through an on-line system, IRBWise.  
Study purpose 
This study is designed to estimate the county-level prevalence and distribution 
of MS throughout Georgia (GA).  In addition, this study will determine if the 
distribution of MS in GA is associated with the distribution of census data, toxic 
release inventory (TRI) data and source emission to outdoor air from the National 
Emissions Inventory database (NET) of criteria air pollutants.   Also, this study will 
attempt to determine which of these three data relate best to the distribution of MS in 
GA.  Lastly, this study will endeavor to determine if there is a dose response 
relationship between the distribution of MS and the census or air pollutant data.    
Data Sources 
The data for this study comes from the National Multiple Sclerosis Society 
(NMSS), the United States Census Bureau, and Scorecard.org, by Environmental 
Defense, which assimilated county-level air and water emissions data in the United 
States. (US Census 2005, Scorecard 2005)  The final population for this study was 
9,072,576 people, including 6247 self-reported MS cases from the NMSS-GA 
chapter. 
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MS data were received from the National Multiples Sclerosis Society’s GA 
chapter in November 2006.   These data included the self-reported MS cases of the 
current MS Society member’s list as of November 2006.  The data obtained for this 
study includes the number of people diagnosed with multiple sclerosis, their gender, 
and their county of residence.  The NMSS, as part of their membership questionnaire, 
originally received this information. 
Selected census data were retrieved for each of the 159 Georgia counties.  
These data included the total county population, the percent female in 2005, the 2005 
female and male population estimates, the percent white and the percent black.  In 
addition, the percent living in the same house in 1995 and 2000, the per capita 
income, in 1999, the square miles land area in 2000, and the people per square mile in 
2005 was also obtained for this study.   
Also, using scorecard.org, which provided a database of Toxic Release 
Inventory (TRI) source emissions from the U.S. Environmental Protection Agency 
(EPA) for various categories of toxicants and criteria air pollutants, county level air 
pollutant emissions were obtained.  The data used for this study included 2002 source 
emissions in pounds:  recognized carcinogens, suspected carcinogens, suspected 
cardiovascular or blood toxicants, recognized developmental toxicants, suspected 
developmental toxicants, suspected endocrine toxicants, suspected endocrine 
toxicants, suspected immunotoxicants, suspected kidney toxicants, suspected 
gastrointestinal or liver toxicants, suspected muscoskeletal toxicants, suspected 
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neurotoxicants, recognized reproductive toxicants, suspected reproductive toxicants 
suspected respiratory toxicants, suspected skin and sense toxicants, acetaldehyde, 
ammonia, formaldehyde, manganese, and lead and lead compounds.   
In addition to these, the National Emissions Inventory (NEI) Air Pollutant 
Emissions Trends data, which were measurements led by the U.S. EPA, were 
obtained through scorecard.org.  NEI is a collection of source emissions to outdoor 
air from state, local, tribal and industrial measures.  From NEI, this study used criteria 
air pollutants reported for 1999 in tons: carbon monoxide, nitrogen oxides, particulate 
matter (PM) 2.5, PM 10, sulfur dioxide, and volatile organic compounds (total, 
selected individual).  Each compound was surveyed for mobile, area, and point 
sources; the three source categories together were termed “all sources.”  
It is important to state this study did not assume source emissions are the same 
as measured concentrations in outdoor air or actual human exposure.  Rather, this 
study used source emissions as a surrogate measure for exposure to environmental air 
pollution, selected groups of toxicants and criteria air pollutants subject to regulation.   
Data Management 
For this study, a MS case was defined as a person being diagnosed previously 
with MS, according to the NMSS entrance survey, and residing in GA.  Furthermore, 
the number of controls was calculated using the 2005 U.S. Census population for 
each county, minus the number of MS cases in that county.   Lastly, prevalence 
signified the county self-reported case prevalence per 100,000 population.   
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  Several assumptions were necessary for this analysis.  We assumed the 
NMSS-GA member list included accurate data members answered truthfully as to 
their diagnosis of MS and their gender.  Also, we assumed the TRI and NEI data were 
received and displayed in scorecard.org’s website and it was accurately reported by 
the private and public sector per the Emergency Planning and Community Right-to-
Know Act of 1986, which established TRI.    
This study used cross-sectional data at several different time points.  The 
study was designed to determine the prevalence of MS in GA and to explore the 
relationship between environmental air pollutants and MS in GA.  With that purpose 
in mind, we used November 2006 cross sectional data from the MS Society’s GA 
chapter.  These data were compared to the county-level emissions data using both 
regression (a measurement of association) and odds ratios.   
Female and male prevalence rates were calculated for each of the counties in 
GA by dividing the number of cases in each county by the total county population 
and multiplying this number by 100,000.  Thus, each of the prevalence ratios shows a 
population-density-controlled rate for each county.  The database was stored in both 
SPSS version 14 (SPSS 2005) and Microsoft Excel 2004 (Microsoft-Corporation 
2004).   These prevalence rates were made into a geographical image using 
CorelDraw by tracing the image of a map of GA and placing the prevalence rates in 
their respective counties.  After this was done, each county was shaded according to 
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the county’s prevalence rate.  This same process was done for total, female, and male, 
MS rates in GA per 100,000 population.   
Statistical Analysis 
Statistical analysis was done using both SPSS version 14 (2005) and 
Microsoft Excel 2004 (Microsoft-Corporation 2004).  Bivariate linear regression was 
used to determine association between the prevalence rates and each of the census 
data or emissions data variables.  Standardized beta values were calculated for each of 
these associations, and the statistical significance was calculated using a two-tailed t-
test.  Finally, R-squared values were also calculated for each model.  R-squared 
represents the amount of variance in the model (this model’s female self reported MS 
prevalence in GA) that can be attributed to the study characteristic (eg. Percent 
female 2005).   
Stepwise multivariate linear regression was calculated using SPSS.  This was 
done with an entry criterion of a p-value of 0.05 and an exit criterion of a p-value of 
0.10.  With this method, we analyzed which of the census and NEI variables were 
most related to the county MS prevalence in GA, overall (total) and by gender. 
Odds ratios (ORs) were calculated for each of the census characteristics, each 
of the toxicants, and each of the criteria air pollutants.  It is important to mention the 
odds ratios in this study referred to the prevalence odds ratio because the cases used 
in this study indicated prevalence, not incidence.  The counties with data for the 
variable being analyzed were separated into quartiles by SPSS for Windows version 
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14.  The total number of cases or controls was added for each of the quartiles and 
these numbers were used to calculate the ORs.  The lowest quartile was always used 
as the reference group.  Then, the 2nd, 3rd and 4th quartiles were compared to the 
lowest quartile using EPI Info version 6.04 (CDC 2001).  Finally, data were analyzed 
statistically at the 0.05, 0.01, 0.001, and 0.0001 levels.  Once all of the analyses were 
done, the tables were constructed using Microsoft Excel 2004.  
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IV.  Results 
Table 1 shows the Multiple Sclerosis cases and self-reported-case prevalence rates by county.   In the 159 counties in 
GA, the prevalence rates varied widely; the rates were not equally distributed from county to county.  Also, these self-reported 
cases are 71.5% female, 22.3% male, and 6.2% unknown gender. 
 
Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Appling 3 3 0 0 17 33 0 
Atkinson 2 1 1 0 25 25 25 
Bacon 1 1 0 0 10 19 0 
Baker 0 0 0 0 0 0 0 
Baldwin 18 8 9 1 40 38 37 
Banks 8 6 2 0 50 76 25 
Barrow 41 32 8 1 68 107 27 
Bartow 60 44 13 3 67 98 29 
Ben Hill 7 4 3 0 40 44 36 
Berrien 9 7 2 0 54 83 24 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Bibb 110 74 28 8 71 89 39 
Bleckley 3 2 0 1 25 32 0 
Brantley 5 3 1 1 32 39 13 
Brooks 4 4 0 0 24 47 0 
Bryan 23 17 3 3 81 118 21 
Bulloch 26 21 2 3 42 67 7 
Burke 5 4 0 1 21 33 0 
Butts 17 10 5 2 81 102 45 
Calhoun 3 3 0 0 50 117 0 
Camden 40 33 5 2 87 144 22 
Candler 7 3 4 0 68 58 77 
Carroll 78 62 13 3 74 116 25 
Catoosa 0 0 0 0 0 0 0 
Charlton 9 7 1 1 83 139 17 
Chatham 160 132 26 2 67 107 23 
Chattahoochee 2 2 0 0 14 32 0 
Chattooga 13 11 1 1 49 86 7 
Cherokee 179 128 40 11 97 140 43 
Clarke 68 46 10 12 65 87 19 
Clay 0 0 0 0 0 0 0 
Clayton 129 91 32 6 48 66 24 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Clinch 5 2 3 0 71 57 87 
Cobb 670 473 154 43 101 142 47 
Coffee 8 6 2 0 20 30 10 
Colquitt 26 17 6 3 59 78 27 
Columbia 95 67 21 7 92 126 41 
Cook 6 6 0 0 37 71 0 
Coweta 92 70 12 10 84 127 22 
Crawford 6 3 2 1 47 47 31 
Crisp 8 6 2 0 36 52 19 
Dade 0 0 0 0 0 0 0 
Dawson 18 12 3 3 91 123 30 
Decatur 8 7 1 0 28 47 7 
Dekalb 547 373 138 36 81 107 42 
Dodge 9 7 1 1 46 75 10 
Dooly 3 1 2 0 26 18 33 
Dougherty 44 38 5 1 46 75 11 
Douglas 92 64 26 2 82 112 47 
Early 5 5 0 0 41 78 0 
Echols 1 0 0 1 24 0 0 
Effingham 29 24 4 1 62 102 17 
Elbert 9 8 1 0 43 74 10 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Emanuel 9 5 3 1 41 44 28 
Evans 4 1 3 0 35 17 54 
Fannin 21 19 2 0 96 169 19 
Fayette 123 84 30 9 118 158 59 
Floyd 72 54 16 2 76 112 35 
Forsyth 144 96 36 12 103 139 50 
Franklin 16 14 2 0 74 126 19 
Fulton 745 511 177 57 81 111 39 
Gilmer 11 9 2 0 40 67 14 
Glascock 3 3 0 0 111 218 0 
Glynn 50 32 12 6 70 86 35 
Gordon 29 19 9 1 58 76 36 
Grady 11 8 2 1 45 63 17 
Greene 15 12 2 1 96 148 26 
Gwinnett 531 382 120 29 73 107 33 
Habersham 17 14 3 0 43 73 15 
Hall 87 66 17 4 52 82 20 
Hancock 3 3 0 0 31 67 0 
Haralson 21 21 0 0 74 146 0 
Harris 15 7 6 2 54 50 44 
Hart 8 7 1 0 33 57 8 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Heard 6 5 1 0 53 87 18 
Henry 142 105 27 10 85 124 32 
Houston 98 74 18 6 78 116 29 
Irwin 2 2 0 0 20 39 0 
Jackson 54 34 17 3 103 131 65 
Jasper 7 5 1 1 53 75 15 
Jeff Davis 3 1 0 2 23 15 0 
Jefferson 8 4 1 3 47 45 13 
Jenkins 3 3 0 0 34 67 0 
Johnson 1 1 0 0 10 23 0 
Jones 25 15 9 1 93 110 68 
Lamar 16 12 2 2 98 142 25 
Lanier 3 3 0 0 40 81 0 
Laurens 23 17 6 0 49 70 26 
Lee 20 12 6 2 64 78 38 
Liberty 23 18 5 0 40 65 17 
Lincoln 2 1 0 1 24 24 0 
Long 1 1 0 0 9 18 0 
Lowndes 52 42 10 0 54 87 21 
Lumpkin 10 6 3 1 41 49 25 
Macon 3 3 0 0 22 43 0 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Madison 25 18 6 1 92 131 44 
Marion 4 3 1 0 55 83 27 
Mcduffie 15 9 6 0 69 79 58 
Mcintosh 6 3 3 0 54 53 55 
Meriwether 16 12 4 0 70 101 36 
Miller 1 1 0 0 16 31 0 
Mitchell 8 5 3 0 34 43 25 
Monroe 11 10 1 0 46 85 8 
Montgomery 5 4 1 0 56 92 22 
Morgan 17 10 3 4 97 111 35 
Murray 0 0 0 0 0 0 0 
Muscogee 127 92 28 7 69 94 32 
Newton 57 43 10 4 66 97 23 
Oconee 30 24 4 2 101 159 27 
Oglethorpe 10 7 3 0 73 101 45 
Paulding 78 63 12 3 69 113 21 
Peach 15 9 6 0 60 71 50 
Pickens 16 10 3 3 56 69 21 
Pierce 5 2 2 1 29 23 24 
Pike 10 8 1 1 62 100 12 
Polk 20 13 3 4 49 65 15 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Pulaski 8 6 2 0 82 109 47 
Putnam 11 7 4 0 55 70 41 
Quitman 1 1 0 0 41 77 0 
Rabun 11 7 2 2 68 87 25 
Randolph 5 2 3 0 68 51 89 
Richmond 133 92 36 5 68 90 38 
Rockdale 62 42 16 4 79 107 41 
Schley 2 2 0 0 49 94 0 
Screven 1 1 0 0 6 13 0 
Seminole 4 2 1 1 43 41 23 
Spalding 35 27 5 3 57 86 17 
Stephens 10 7 1 2 40 54 8 
Stewart 0 0 0 0 0 0 0 
Sumter 14 10 4 0 43 58 25 
Talbot 8 6 1 1 119 170 32 
Taliaferro 0 0 0 0 0 0 0 
Tattnall 9 6 3 0 39 61 22 
Taylor 3 3 0 0 34 67 0 
Telfair 3 3 0 0 23 53 0 
Terrell 4 4 0 0 37 72 0 
Thomas 24 21 2 1 54 89 9 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Tift 15 11 2 2 37 53 10 
Toombs 11 10 0 1 40 71 0 
Towns 16 12 4 0 155 223 81 
Treutlen 3 1 2 0 44 30 58 
Troup 29 24 4 1 47 74 13 
Turner 4 3 1 0 42 61 22 
Twiggs 6 3 3 0 58 56 61 
Union 18 12 6 0 91 120 62 
Upson 23 16 5 2 83 111 38 
Walker 3 3 0 0 5 9 0 
Walton 59 41 16 2 78 106 43 
Ware 14 10 4 0 41 58 23 
Warren 3 3 0 0 49 93 0 
Washington 7 6 1 0 35 54 11 
Wayne 12 6 6 0 42 44 41 
Webster 1 1 0 0 44 88 0 
Wheeler 1 0 0 1 15 0 0 
White 17 12 3 2 71 99 25 
Whitfield 1 1 0 0 1 2 0 
Wilcox 3 2 1 0 34 53 20 
Wilkes 5 4 1 0 48 74 20 
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Table 1.  Multiple Sclerosis in GA by County: Self-Reported Cases and Prevalence Rates per 100,000 Population.  
County name 
Nov. 
2005 
total 
cases  
(N= 
6247) 
Nov. 
2005 
female 
cases 
(N= 
4466) 
Nov. 
2005 
male 
cases 
(N= 
1392) 
Nov. 2005 
unknown 
gender 
cases 
(N=389) 
Nov. 2005 
total 
prevalence  
rates* (per 
100,000 
people) 
Nov. 2005 
female 
prevalence 
rates* (per 
100,000 
women) 
Nov. 2005 
male 
prevalence 
rates* (per 
100,000 men) 
Wilkinson 10 5 4 1 99 94 83 
Worth 14 6 8 0 64 52 76 
Mean 39.2 28.1 8.8 2.4 53.2 75.9 23.3 
Standard Dev. 101.5 71.1 23.9 6.9 28.5 42.9 20.9 
Median 10 7 2 0 49.4 74.4 21.8 
*Prevalence rates are calculated using the number of cases in the county divided by the county's 2005 population 
estimate (Census-Bureau, Jan 2007) multiplied by 100,000.  The denominators for the total, female, and male rates 
were the total county population, the female county population, and the male population, respectively.   
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In figure 1, the overall self-reported-case prevalence rates at the county level 
were usually lower than the rates seen for females (figure 2) and higher than for male 
rates (figure 3).  Also, the darker areas seem to center around Cobb, Fulton and 
Dekalb County.  These counties are counties of metropolitan Atlanta, the most 
developed and urbanized setting in Georgia. 
 In figure 2, the self-reported-case prevalence rates are generally higher than 
those seen in figures 1 and 3, which depict overall self-reported-case prevalence rates 
and the male self-reported-case prevalence rates , respectively.  Also, the dark area 
seems to center around Cobb, Fulton and Dekalb County.  These counties are 
metropolitan counties of Atlanta, the most developed and urbanized setting in 
Georgia. 
In figure 3 the male MS self- reported case prevalence rates are markedly 
lower than those seen in the female MS self-reported-case prevalence rates (figure 2).  
Also, while there is a slight pattern of higher rates around Atlanta, the general pattern 
seems more dispersed for males than for females.   
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Table 2 shows the results of bivariate linear regression for self-reported 
prevalence and county level census data.  We observed that the strength of the 
association between total MS rates and census data were largely driven by the female 
rates.  Also, many of the variables show many highly significant values, especially 
per capita income.  For these variables it was unlikely the association between the MS 
self-reported prevalence and the variable was due to chance alone, given the sample 
sizes.   
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Table 2: Bivariate Linear Regression for Self-Reported-Case Prevalence and County Level Census Data.   
  Variable N 
(counties 
included 
in the 
analysis) 
Total Rates 
and 
standardized 
beta (β) 
P-
value 
of 
betaa 
(total 
rates)
R2 of 
the 
total 
rate 
Female 
Rates and 
standardized 
beta (β) 
P-
value 
of 
betaa 
(female 
rates) 
R2  of 
the 
female 
Rate 
Male rates 
and 
standardized 
beta (β) 
P-
value 
of 
betaa 
male 
rates)
R2 of 
the 
male 
rate 
Total 
population 159 0.259*** 0.001 0.067 0.237** 0.003 0.056 0.175* 0.027 0.031
Percent 
female  159 0.143 0.073 0.02 0.098 0.217 0.010 0.142 0.075 0.020
Female 
population  159 0.260*** 0.001 0.068 0.238** 0.003 0.056 0.176* 0.027 0.031
Male 
population  159 0.258** 0.001 0.067 0.237** 0.003 0.056 0.174* 0.028 0.03 
Percent 
white 159 0.036 0.655 0.001 0.007 0.934 0.000 0.085 0.284 0.007
Percent 
black 159 -0.242** 0.002 0.058 -0.230** 0.003 0.053 -0.102 0.201 0.010
Percent 
living in 
the same 
house  
159 -0.264*** 0.001 0.070 -0.263*** 0.001 0.069 -0.263*** 0.001 0.069
Per capita 
income  159 0.522**** 0.000 0.272 0.459**** 0.000 0.211 0.459**** 0.000 0.211
Square 
miles land 159 -0.101 0.206 0.010 -0.116 0.147 0.013 -0.116 0.147 0.013
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analysis) 
Total Rates 
and 
standardized 
beta (β) 
P-
value 
of 
betaa 
(total 
rates)
R2 of 
the 
total 
rate 
Female 
Rates and 
standardized 
beta (β) 
P-
value 
of 
betaa 
(female 
rates) 
R2  of 
the 
female 
Rate 
Male rates 
and 
standardized 
beta (β) 
P-
value 
of 
betaa 
male 
rates)
R2 of 
the 
male 
rate 
area 
People 
per 
square 
mile 
159 0.262*** 0.001 0.069 0.230** 0.004 0.053 0.230** 0.004 0.053
a P-values are calculated using a two-tailed t distribution                                                                                                  
*Values are significant at the 0.05 level                                                                                                                            
**Values are significant at the 0.01 level                                                                                                                          
***Values are significant at the 0.001 level                                                                                                                       
****Values are significant at the 0.0001 level 
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Table 3 shows the association between toxicants and environmental pollutants 
as county level emissions data and the total, female, and male self-reported-case 
prevalence rates of MS using bivariate linear regression.  No statistically significant 
values were found for this table when using an alpha value of 0.05.  However, two of 
the associations—Total rates and suspected cardiovascular or blood toxicants and 
suspected developmental toxicant—were very near to statistical significance.  
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Table 3: Bivariate Linear Regression for Self-Reported-Case Prevalence versus County Level Emissions Data.   
   Variable N 
(counties 
included 
in the 
analysis)
Total 
rates 
and 
standard 
beta (β) 
P-value 
of 
betaa 
(total 
rates) 
R2 of 
the 
total 
rate 
Female 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(female 
rates) 
R2  of 
the 
female 
rate 
Male 
rates 
and 
standard 
beta (β) 
P-value 
of 
betaa 
male 
rates) 
R2 of 
the 
male 
rate 
Recognized 
carcinogens 83 -0.052 0.640 0.003 -0.064 0.563 0.004 0.002 0.987 0.000 
Suspected 
carcinogens 63 -0.087 0.496 0.008 -0.066 0.609 0.004 -0.029 0.822 0.001 
Suspected 
cardiovascular 
or blood 
toxicants 
99 0.167 0.098 0.028 0.160 0.115 0.025 0.138 0.172 0.019 
Recognized 
development 
toxicants  
79 0.196 0.084 0.038 0.181 0.111 0.033 0.112 0.325 0.013 
Suspected 
developmental 
toxicants  
94 0.022 0.831 0.000 0.004 0.973 0.000 0.107 0.303 0.012 
Suspected 
endocrine 
toxicants  
64 -0.049 0.705 0.002 0.001 0.991 0.000 -0.072 0.574 0.005 
Suspected 
immunotoxicants 
96 0.056 0.586 0.003 0.087 0.401 0.007 0.016 0.877 0.000 
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Table 3: Bivariate Linear Regression for Self-Reported-Case Prevalence versus County Level Emissions Data.   
   Variable N 
(counties 
included 
in the 
analysis)
Total 
rates 
and 
standard 
beta (β) 
P-value 
of 
betaa 
(total 
rates) 
R2 of 
the 
total 
rate 
Female 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(female 
rates) 
R2  of 
the 
female 
rate 
Male 
rates 
and 
standard 
beta (β) 
P-value 
of 
betaa 
male 
rates) 
R2 of 
the 
male 
rate 
Suspected 
kidney toxicants  
100 0.073 0.472 0.005 0.058 0.564 0.003 0.097 0.338 0.009 
Suspected 
gastrointestinal  
or liver toxicants  
107 0.067 0.492 0.005 0.098 0.317 0.010 0.022 0.818 0.001 
Suspected 
muscoskeletal 
toxicants  
32 -0.031 0.867 0.001 0.020 0.912 0.000 -0.081 0.658 0.007 
Suspected 
neurotoxicants  
104 0.020 0.837 0.000 0.023 0.819 0.001 0.034 0.734 0.001 
Recognized 
reproductive 
toxicants  
70 -0.010 0.933 0.000 0.005 0.968 0.000 0.008 0.945 0.000 
Suspected 
reproductive 
toxicants  
103 0.030 0.767 0.001 0.036 0.721 0.001 0.036 0.721 0.001 
Suspected 
respiratory 
toxicants  
103 0.064 0.518 0.004 0.096 0.332 0.009 0.022 0.823 0.000 
Suspected skin 
or sense 
toxicants 
101 0.055 0.586 0.003 0.090 0.372 0.008 0.010 0.920 0.000 
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Table 3: Bivariate Linear Regression for Self-Reported-Case Prevalence versus County Level Emissions Data.   
   Variable N 
(counties 
included 
in the 
analysis)
Total 
rates 
and 
standard 
beta (β) 
P-value 
of 
betaa 
(total 
rates) 
R2 of 
the 
total 
rate 
Female 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(female 
rates) 
R2  of 
the 
female 
rate 
Male 
rates 
and 
standard 
beta (β) 
P-value 
of 
betaa 
male 
rates) 
R2 of 
the 
male 
rate 
Acetaldehyde 14 -0.161 0.583 0.026 -0.202 0.489 0.041 0.061 0.835 0.004 
Ammonia in  39 0.139 0.397 0.019 0.106 0.520 0.011 0.158 0.337 0.025 
Formaldehyde 27 -0.138 0.493 0.019 -0.260 0.190 0.068 0.144 0.473 0.021 
Lead/ lead  
compounds 49 -0.146 0.318 0.021 -0.050 0.734 0.002 -0.164 0.260 0.027 
Manganese 
compounds  30 0.046 0.810 0.002 0.126 0.506 0.016 -0.062 0.744 0.004 
Methanol 
compounds 34 0.051 0.775 0.003 0.008 0.965 0.000 0.214 0.224 0.046 
The measurements for toxicants and selected produced compounds were reported in pounds for the year 2002.    
a P-values are calculated using a two-tailed t distribution                                                                                                       
*Values are significant at the 0.05 level                                                                                                                                 
**Values are significant at the 0.01 level                                                                                                                                 
***Values are significant at the 0.001 level                                                                                                                             
****Values are significant at the 0.0001 level 
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  Table 4 shows the associations between selected criteria air pollutants and 
overall MS self-reported-case prevalence using bivariate linear regression.  The 
highest association and highest significance was observed for PM-10 and PM-2.5 
mobile sources.  Relatively weaker but still significant associations were observed 
with nitrogen oxides, carbon monoxide and volatile organic compounds.  Finally, the 
association with these selected criteria air pollutants and female self-reported-case 
prevalence rates were generally stronger than those observed with male self-reported-
case prevalence rates. 
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Table 4: Bivariate Linear Regression: Total Self-Reported-Case Prevalence vs. Criteria Air Pollutant Data.   
   Variable N 
(counties 
included 
in the 
analysis) 
Total 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(total 
rates) 
R2 of 
the 
total 
rate 
Female 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(female 
rates) 
R2  of 
the 
female 
rate 
Male 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
male 
rates) 
R2 of 
the 
male 
rate 
Carbon 
Monoxide 
(mobile) 
158 0.234** 0.003 0.055 0.208** 0.009 0.043 0.167* 0.036 0.028 
Carbon 
monoxide   
(area) 
158 -0.078 0.330 0.006 -0.097 0.223 0.009 0.005 0.946 0.000 
Carbon 
monoxide   
(all) 
158 0.193* 0.015 0.037 0.170* 0.033 0.029 0.144 0.072 0.021 
Nitrogen 
oxides   
(mobile) 
158 0.242** 0.002 0.059 0.215** 0.007 0.046 0.176* 0.027 0.031 
Nitrogen 
oxides   
(area) 
158 -0.003 0.974 0.000 0.03 0.705 0.001 -0.041 0.606 0.002 
Nitrogen 
oxides   
(all) 
158 0.212** 0.007 0.045 0.213** 0.007 0.045 0.130 0.103 0.017 
PM-2.5   
(mobile) 158 0.282*** 0.000 0.079 0.264*** 0.001 0.07 0.175* 0.028 0.030 
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Table 4: Bivariate Linear Regression: Total Self-Reported-Case Prevalence vs. Criteria Air Pollutant Data.   
   Variable N 
(counties 
included 
in the 
analysis) 
Total 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(total 
rates) 
R2 of 
the 
total 
rate 
Female 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(female 
rates) 
R2  of 
the 
female 
rate 
Male 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
male 
rates) 
R2 of 
the 
male 
rate 
PM-2.5   
(area) 158 -0.093 0.247 0.009 -0.107 0.182 0.011 -0.001 0.992 0.000 
PM-2.5   
(all) 158 0.107 0.179 0.012 0.073 0.363 0.005 0.142 0.076 0.020 
PM-10   
(mobile) 158 0.276*** 0.000 0.076 0.268*** 0.001 0.072 0.159* 0.046 0.025 
PM-10 
(area) 158 -0.045 0.578 0.002 -0.058 0.470 0.003 0.020 0.802 0.000 
PM-10 
(all) 158 0.192* 0.016 0.037 0.179* 0.024 0.032 0.133 0.097 0.018 
Sulfur 
Dioxide   
(mobile) 
158 0.136 0.089 0.018 0.118 0.141 0.014 0.136 0.089 0.018 
Sulfur 
Dioxide   
(area) 
158 0.062 0.436 0.004 0.045 0.571 0.002 0.074 0.356 0.005 
Sulfur 
Dioxide   
(all) 
158 0.083 0.297 0.007 0.105 0.189 0.011 0.034 0.675 0.001 
VOCs 
(mobile) 158 0.231** 0.003 0.054 0.206** 0.010 0.042 0.164* 0.039 0.027 
VOCs 
(area) 158 0.211** 0.008 0.045 0.196 0.013 0.039 0.138 0.083 0.019 
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Table 4: Bivariate Linear Regression: Total Self-Reported-Case Prevalence vs. Criteria Air Pollutant Data.   
   Variable N 
(counties 
included 
in the 
analysis) 
Total 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(total 
rates) 
R2 of 
the 
total 
rate 
Female 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
(female 
rates) 
R2  of 
the 
female 
rate 
Male 
rates 
and 
standard 
beta (β) 
P-value 
of betaa 
male 
rates) 
R2 of 
the 
male 
rate 
VOCs  
(all) 158 0.243** 0.002 0.059 0.219** 0.006 0.048 0.174* 0.029 0.030 
a p-values are calculated using a two-tailed t distribution                                                                                                 
VOCs are volatile organic compounds.  Also, the selected air pollutants were measured in 1999 and they were 
measured in tons of emissions to outdoor air.                                                                                                                  
*Values are significant at the 0.05 level                                                                                                                           
**Values are significant at the 0.01 level                                                                                                                         
***Values are significant at the 0.001 level                                                                                                                      
****Values are significant at the 0.0001 level 
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In table 5, using census, NEI and Total self-reported MS prevalence rates, the 
last model for stepwise multiple linear regression selected two characteristics, per-
capita income and PM-10 from area sources.   Also, these two characteristics together 
had ability for this model to predict MS rates than per capita income alone.  In these 
models, the beta coefficient was positive.  This means as per capita income and PM-
10 emissions to outdoor air from area sources increased, the total self-reported-case 
prevalence rates increased.  Finally, the r-squared value estimated the ability for the 
model to predict the total self-reported-case prevalence rates by county.  Therefore, in 
this model 26.2% of the total self-reported-case prevalence might have been 
explained by per capita income and PM-10 from area sources.  
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Table 5: Multivariate Linear Regression, Total MS Self-Reported-Case Prevalence Rates and Census and NEI air pollutants 
Model 
Total rates and 
standardized beta (β) 
P-value of betaa 
(total rates) 
R2 of the 
total rate 
Per capita Income 0.512 0.000 0.262 
Per Capita Income and PM-10 (area sources, 1999) 
     Per Capita Income 
     PM-10 (area sources, 1999) 
0.535
0.545
-0.158
0.024
0.000
0.024
0.286 
 
 
This analysis was done using stepwise multivariate linear regression with an acceptance p-value of 0.05 and an elimination 
p-value of 0.10.  This analysis included only census data and selected criteria air pollutants.   
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  As with the total rates, using census data and NEI, the final model 
summarized here for the female MS self-reported prevalence rates (table 6) selected 
per-capita income and PM-10 emissions to outdoor air from area sources for 
predicting female self-reported-case prevalence rates using multivariate linear 
regression.  Also, the association was positive.  The final model with the r-squared 
value of 0.225, suggesting 22.5% of the variance might be able to be explained using 
these two variables.
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Table 6: Multivariate Linear Regression, Female MS Self-Reported-Case Prevalence Rates and Census and NEI  air pollutants  
Model 
Total Rates and 
Standardized Beta (β) 
P-value of Betaa 
(total rates) 
R2 of the 
Total Rate 
Per capita Income 0.448 0.000 0.201 
Per Capita Income and PM-10 (area sources, 1999) 
     Per Capita Income 
     PM-10 (area sources, 1999) 
0.474
0.481
-0.158
0.030
0.000
0.030
0.225 
 
 
This analysis was done using stepwise multivariate linear regression with an acceptance p-value of 0.05 and an elimination p-
value of 0.10.  This analysis included only census data and selected criteria air pollutants. 
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In table 7, using census data, NEI and male MS self-reported prevalence rates, 
stepwise multivariate linear regression selected only per capita income was included 
to estimate the self-reported-case prevalence of MS in males.  The association 
calculated by the beta value was less than the association between per capita income 
and female or total rates.  Lastly, the r-squared estimate was 0.114, or 11.4% of the 
variance in male MS rates might have been explained using this model.  
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Table 7: Multivariate Linear Regression, Male MS Self-Reported-Case Prevalence Rates and Census and NEI air pollutants  
Model 
Total Rates and 
Standardized Beta (β) 
P-value of Betaa 
(total rates) 
R2 of the 
Total Rate 
Per capita Income 0.337 0.000 0.114 
This analysis was done using stepwise multivariate linear regression with an acceptance p-value of 0.05 and an elimination 
p-value of 0.10.  This analysis included only census data and selected criteria air pollutants. 
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Table 8 shows steadily increasing odds ratios for total MS self-reported-case 
prevalence for several characteristics derived from U.S. Census data when separated 
by quartile: total population, male population, per capita income, and people per 
square mile.  Also, the percent black and percent white show significantly strong but 
varying ORs.  Also, people living in the same household in years 2000 and 2005 had 
ORs less than one.  
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Table 8: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Census Data and Total Self-Reported MS cases 
 Variable OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa of 
the 
second 
quartile's 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa of 
the third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa of 
the fourth 
quartile's 
OR  
N 
(Number 
of people 
used for 
the OR) 
Total 
population 1.00 1.04 (0.85,1.27) 934957 1.04 (0.87,1.26) 1509185 1.52**** (1.28,1.81) 7208676 
Percent 
female  1.00 1.19**** (1.11,1.27) 5264143 1.04 (0.97,1.12) 4278364 0.93 (0.86,1.02) 3576459 
Female 
population  1.00 1.05 (0.86,1.29) 936425 1.09 (0.90,1.32) 1508117 1.56**** (1.31,1.85) 7209020 
Male 
population  1.00 1.02 (0.83,1.25) 936038 1.11 (0.92,1.34) 1510076 1.55**** (1.31,1.85) 7207260 
Percent 
white 1.00 0.85**** (0.78,0.92) 4517995 1.16**** (1.09,1.23) 6019018 0.89** (0.82,0.96) 4929913 
Percent 
black 1.00 1.24**** (1.15,1.33) 4737748 0.89* (0.81,0.98) 2890160 1.09* (1.01,1.17) 4967140 
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Table 8: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Census Data and Total Self-Reported MS cases 
 Variable OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa of 
the 
second 
quartile's 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa of 
the third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa of 
the fourth 
quartile's 
OR  
N 
(Number 
of people 
used for 
the OR) 
Percent 
living in 
the same 
house  1.00 0.69**** (0.64,0.74) 7847447 0.58**** (0.52,0.65) 6858190 0.62**** (0.54,0.70) 6697317 
Per capita 
income  1.00 1.17 (0.97,1.41) 1293891 1.61**** (1.38,1.89) 2656723 2.22**** (1.92,2.58) 6158670 
Square 
miles land  1.00 1.11** (1.03,1.19) 4586763 1.01 (0.93,1.09) 3796684 0.94 (0.86,1.02) 3818753 
People 
per sq. 
mile 1.00 1.27* (1.05,1.56) 1099364 1.36*** (1.13,1.64) 1595362 1.90**** (1.60,2.26) 7085554 
Each variable under analysis included 159 counties in GA.                                                                                                         
a 95% CI is calculated using the case-control study estimation model                                                                                        
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables                                                   
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables                                                 
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables                                             
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables      
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Table 9 shows total population, total female population, total male population, 
per capita income, and people per square mile had steadily increasing odds ratios for 
female MS self-reported-case prevalence across increasing quartiles.  Also, as in 
Table 8, the percent living in the same house showed ORs less than one; however, 
this relationship did not continuously decrease across increasing quartiles for females.   
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Table 9: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Census Data and Female Self-Reported MS 
cases 
  Variable OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa of 
the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa of 
the third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa of 
the fourth 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Total 
population 1.00 1.04 (0.82,1.33) 471185 1.05 (0.84,1.31) 758303 1.52**** (1.24,1.86) 3647621 
Percent 
female  1.00 1.14* (1.05,1.23) 2617130 0.99 (0.91,1.08) 2140378 0.89* (0.81,0.99) 1801100 
Female 
population  1.00 1.08 (0.85,1.38) 469590 1.11 (0.88,1.38) 759228 1.55**** (1.27,1.92) 3648235 
Male 
population  1.00 1.03 (0.80,1.31) 473126 1.18 (0.94,1.48) 759731 1.58**** (1.29,1.95) 3645486 
Percent 
white 1.00 0.88* (0.80,0.97) 2307722 1.20**** (1.12,1.32) 3053523 0.95 (0.87,1.04) 2501961 
Percent 
black 1.00 1.21**** (1.11,1.32) 2370527 0.87* (0.77,0.97) 1450737 1.02 (0.94,1.12) 2522312 
Percent 
living in 
same 
house  1.00 0.68**** (0.63,0.74) 3962140 0.61**** (0.54,0.70) 3457814 0.59**** (0.51,0.69) 3376835 
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Table 9: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Census Data and Female Self-Reported MS 
cases 
  Variable OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa of 
the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa of 
the third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa of 
the fourth 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Per capita 
income  1.00 1.21 (0.97,1.51) 648920 1.65**** (1.37,2.00) 1346989 2.23**** (1.86,2.67) 3098085 
Square 
miles land  1.00 1.12* (1.03,1.22) 2331699 1.07 (0.98,1.18) 1911463 0.96 (0.87,1.06) 1934333 
People 
per sq. 
mile 1.00 1.22 (0.96,1.54) 554040 1.38** (1.11,1.71) 802485 1.85**** (1.51,2.27) 3585499 
Each variable under analysis included159 counties in GA.                                                                                                       
a 95% CI is calculated using the case-control study estimation model                                                                                       
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables                                                 
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables                                                
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables                                            
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables      
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Table 10 shows MS self-reported-case prevalence for the male population 
showed no consistent results; however, the total population, the female population, 
the male population, and the per capita income showed increasing odds ratios starting 
from the second quartile.  Also, the percent living in the same house seems to have a 
protective effect, i.e. OR and CI consistently less than 1.00. 
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Table 10: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Census Data and Male Self-Reported MS 
cases 
  Variable OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile's 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Total 
population 1.00 0.89 
(0.58, 
1.37) 463772 0.97 
(0.65, 
1.43) 750882 1.43* 
(1.01, 
2.05) 3561055
Percent 
female  1.00 1.22** 
(1.06, 
1.41) 2647012 1.1 
(0.93, 
1.29) 2137986 0.99 
(0.82, 
1.18) 1775359
Female 
population  1.00 0.85 
(0.55, 
1.31) 466835 0.98 
(0.66, 
1.45) 748889 1.44* 
(1.01, 
2.06) 3560785
Male 
population  1.00 0.85 
(0.56, 
1.30) 462912 0.86 
(0.58, 
1.15) 750345 1.36 
(0.96, 
1.92) 3561774
Percent 
white 1.00 0.75** 
(0.63, 
0.90) 2210272 1.06 
(0.93, 
1.20) 2965495 0.76*** 
(0.65, 
0.89) 2427952
Percent 
black 1.00 1.29** 
(1.10, 
1.51) 2367221 1.01 
(0.81, 
1.24) 1439423 1.27** 
(1.08, 
1.49) 2444828
Percent 
living in 
same 
house  1.00 0.70****
(0.60, 
0.82) 3885306 0.50****
(0.38, 
0.65) 3400375 0.69*** 
(0.53, 
0.90) 3320481
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Table 10: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Census Data and Male Self-Reported MS 
cases 
  Variable OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile's 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Per capita 
income  1.00 0.96 
(0.65, 
1.42) 644971 1.41* 
(1.03, 
1.95) 1309734 2.04****
(1.51, 
2.77) 3060585
Square 
miles land 
area 2000 1.00 1.13 
(0.97, 
1.32) 2255064 0.90 
(0.76, 
1.07) 1885221 0.92 
(0.78, 
1.09) 1884420
People 
per sq. 
mile 1.00 1.43 
(0.93, 
2.20) 545324 1.26 
(0.84, 
1.91) 792877 2.01*** 
(1.38, 
2.94) 3500055
Each variable under analysis includes 159 counties in GA.                                                                                                
a 95% CI is calculated using the case-control study estimation model                                                                                
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables                                          
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables                                       
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables                                     
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables      
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Table 11 showed increases in the odds ratios for total MS self-reported cases, 
and tended to increase from the second to the fourth quartiles for county level 
emissions to outdoor air recognized developmental toxicants, suspected endocrine 
toxicants, suspected immunotoxicants, suspected kidney toxicants and ammonia.  For 
many of these variables, only the fourth quartile showed statistical significance. Also, 
there seemed to be statistically significant lower odds ratios for recognized 
carcinogens.   
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Table 11: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Total Self-
Reported MS cases  
Variable (# of 
counties in 
analysis for 
each 
variableb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Recognized 
Carcinogens 
(83)  1.00 0.43****
(0.40, 
0.46) 2683293 0.46**** 
(0.43, 
0.49) 3977208 0.44****
(0.41, 
0.48) 3188848 
Suspected 
Carcinogens 
(63)   1.00 1.15** 
(1.05, 
1.27) 2800765 0.88* 
(0.79, 
0.98) 2112213 1.15** 
(1.05, 
1.25) 4245365 
Suspected 
Cardio-
vascular or 
Blood 
Toxicants (99)   1.00 1.09 
(0.97, 
1.23) 1796302 1.04 
(0.93, 
1.15) 2975051 1.19*** 
(1.08, 
1.31) 4844048 
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Table 11: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Total Self-
Reported MS cases  
Variable (# of 
counties in 
analysis for 
each 
variableb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Recognized 
Develop-
mental 
toxicants (79)   1.00 0.90* 
(0.81, 
1.00) 2358067 1.04 
(0.95, 
1.15) 2989780 1.08 
(0.98, 
1.18) 3881857 
Suspected 
Develop-
mental 
toxicants (94)   1.00 1.04 
(0.94, 
1.15) 2249010 0.92 
(0.84, 
1.02) 3073401 1.16*** 
(1.06, 
1.27) 4435056 
Suspected 
Endocrine 
toxicants (64)   1.00 0.92 
(0.83, 
1.02) 2208012 0.95 
(0.87, 
1.04) 3074432 1.15*** 
(1.06, 
1.25) 4151693 
Suspected 
Immuno-
toxicants (96)   1.00 0.74****
(0.67, 
0.82) 2319209 0.96 
(0.87, 
1.04) 3165315 1.10* 
(1.02, 
1.20) 4769708 
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Table 11: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Total Self-
Reported MS cases  
Variable (# of 
counties in 
analysis for 
each 
variableb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Suspected 
Kidney 
toxicants (100)  1.00 1.03 
(0.91, 
1.15) 1986463 1.07 
(0.96, 
1.19) 3024089 1.26****
(1.15, 
1.39) 4653514 
Suspected 
Gastro-
intestinal or 
liver toxicants 
(107)   1.00 1.20** 
(1.08, 
1.35) 2096331 1.04 
(0.93, 
1.15) 3101108 1.34****
(1.21, 
1.47) 4699751 
Suspected 
Musco-
skeletal 
toxicants (32)   1.00 1.09 
(0.99, 
1.19) 2601356 0.96 
(0.87, 
1.07) 2387914 1.29****
(1.18, 
1.41) 2617585 
Suspected 
Neuro-
toxicants (104)  1.00 1.05 
(0.95, 
1.15) 2766274 0.86** 
(0.78, 
0.95) 2611959 1.16*** 
(1.06, 
1.26) 4723348 
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Table 11: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Total Self-
Reported MS cases  
Variable (# of 
counties in 
analysis for 
each 
variableb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Recognized 
Reproductive 
toxicants (70)  1.00 1.03 
(0.93, 
1.14) 2506688 0.86* 
(0.77, 
0.97) 1965624 1.16*** 
(1.06, 
1.27) 4299971 
Suspected 
Reproductive 
toxicants (103)  1.00 1.20*** 
(1.08, 
1.34) 2265535 1.08 
(0.97, 
1.19) 2981303 1.32****
(1.20, 
1.45) 4734854 
Suspected 
Respiratory 
Toxicants 
(103)   1.00 1.04 
(0.94, 
1.16) 2109269 0.92 
(0.84, 
1.01) 3229846 1.21****
(1.11, 
1.31) 4797755 
Suspected 
Skin or Sense 
Toxicants 
(101)   1.00 1.03 
(0.93, 
1.14) 2222602 0.90* 
(0.81, 
0.99) 3063788 1.19****
(1.09, 
1.29) 4764846 
66 
 
Table 11: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Total Self-
Reported MS cases  
Variable (# of 
counties in 
analysis for 
each 
variableb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Acetaldehyde 
(14)   1.00 0.75 
(0.55, 
1.03) 277007 0.88 
(0.72, 
1.09) 692052 0.91 
(0.73, 
1.14) 513424 
Ammonia (39)   1.00 0.91 
(0.78, 
1.05) 1684506 1.16** 
(1.05, 
1.27) 2564465 1.15** 
(1.06, 
1.25) 3195643 
Formaldehyde 
(27)   1.00 1.45** 
(1.14, 
1.84) 472234 1.32** 
(1.08, 
1.61) 999745 1.53****
(1.26, 
1.84) 1410500 
Lead/ lead  
compounds 
(49)   1.00 0.92 
(0.81, 
1.03) 1777914 0.83** 
(0.74, 
0.93) 1947538 1.14** 
(1.04, 
1.25) 2454203 
Manganese 
compounds 
(30)    1.00 1 
(0.87, 
1.16) 1819989 1.32*** 
(1.14, 
1.53) 1313616 0.96 
(0.82, 
1.14) 1009772 
Methanol (34)   1.00 1.14 
(0.99, 
1.31) 1642066 1.12 
(0.97, 
1.30) 1334797 1.05 
(0.91, 
1.21) 1336137 
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Table 11: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Total Self-
Reported MS cases  
Variable (# of 
counties in 
analysis for 
each 
variableb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
The measurements for toxicants and selected produced compounds were reported in pounds for the year 2002.                 
a 95% CI is calculated using the case-control study estimation model.                                                                                    
b Every county that had information concerning the respective variable was included.  The total number of counties in 
GA is 159 at the time of this study.                                                                                                                                          
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables.                                              
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables.                                             
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables.                                         
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables. 
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Table 12 showed small to modest increases in the odds ratios for female MS 
self-reported cases, and tended to increase from the second to the fourth quartiles of 
county level emissions in pounds to outdoor air recognized developmental toxicants, 
suspected endocrine toxicants, suspected immunotoxicants, suspected kidney 
toxicants and ammonia.  Also, there seemed to be lower odds ratios for recognized 
carcinogens; the values were similar across quartiles.   
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Table 12: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Female Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile'
s OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile'
s OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartil
e's OR 
N 
(Number 
of 
people 
used for 
the OR) 
Recognized 
Carcinogens 
(83)  1.00 
0.86** (0.77, 0.96) 1345737 0.89* 
(0.81, 
0.98) 2004536 0.85** 
(0.77, 
0.94) 1626595 
Suspected 
Carcinogens 
(63)   1.00 
1.14* (1.02, 1.27) 1428998 0.92 
(0.81, 
1.05) 1080212 1.12* 
(1.01, 
1.24) 2155182 
Suspected 
Cardio-
vascular or 
Blood 
Toxicants (99)   1.00 
1.02 (0.92, 1.21) 908939 1.04 
(0.92, 
1.18) 1499244 1.16** 
(1.04, 
1.31) 2457076 
Recognized 
Develop-
mental 
toxicants (79)   1.00 
0.92 (0.81, 1.04) 1181017 1.01 
(0.91, 
1.14) 1513394 1.04 
(0.93, 
1.16) 1979912 
Suspected 
Develop-
mental 
toxicants (94)   1.00 
1.04 (0.92, 1.17) 1140228 0.94 
(0.84, 
1.06) 1544766 1.12 
(1.01, 
1.24) 2255240 
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Table 12: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Female Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile'
s OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile'
s OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartil
e's OR 
N 
(Number 
of 
people 
used for 
the OR) 
Suspected 
Endocrine 
toxicants (64)   1.00 
0.94 (0.83, 1.07) 1126196 1.01 
(0.90, 
1.12) 1551054 1.14** 
(1.04, 
1.26) 2109476 
Suspected 
Immuno-
toxicants (96)   1.00 
0.72**** (0.64, 0.82) 1175080 0.96 
(0.86, 
1.06) 1584123 1.07 
(0.97, 
1.17) 2423900 
Suspected 
Kidney 
toxicants (100)  1.00 
1.04 (0.90, 1.19) 1006583 1.10 
(0.97, 
1.24) 1516143 1.24*** 
(1.10, 
1.39) 2366472 
Suspected 
Gastro-
intestinal or 
liver toxicants 
(107)   1.00 
1.15* (1.01, 1.31) 1056961 1.05 
(0.93, 
1.19) 1563048 1.28****
(1.15, 
1.44) 2390813 
Suspected 
Musco-skeletal 
toxicants (32)   1.00 
1.03 (0.92, 1.15) 1311624 0.96 
(0.85, 
1.09) 1214744 1.29****
(1.16, 
1.43) 1313325 
Suspected 
Neuro-
toxicants (104)  
1.00 1.07 (0.95, 1.20) 1385840 0.89 
(0.79, 
1.01) 1323064 1.14* 
(1.03, 
1.26) 2398195 
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Table 12: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Female Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile'
s OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile'
s OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartil
e's OR 
N 
(Number 
of 
people 
used for 
the OR) 
 
Recognized 
Reproductive 
toxicants (70) 1.00 
1.05 (0.93, 1.18) 1257874 0.88 
(0.77, 
1.01) 993398 1.13* 
(1.01, 
1.25) 2182681 
Suspected 
Reproductive 
toxicants (103)  1.00 
1.15* (1.01, 1.31) 1144559 1.09 
(0.97, 
1.23) 1498011 1.25****
(1.12, 
1.40) 2408274 
Suspected 
Respiratory 
Toxicants 
(103)   1.00 
1.05 (0.93, 1.19) 1065348 0.95 
(0.85, 
1.06) 1624733 1.19*** 
(1.07, 
1.32) 2438482 
Suspected 
Skin or Sense 
Toxicants 
(101)   1.00 
1.03 (0.91, 1.16) 1124204 0.94 
(0.84, 
1.05) 1538373 1.18* 
(1.06, 
1.30) 2421997 
Acetaldehyde 
(14)   1.00 
0.9 (0.62, 1.30) 138622 0.89 
(0.69, 
1.15) 358164 1.08 
(0.83, 
1.40) 262337 
Ammonia (39)   1.00 0.91 
(0.76, 
1.08) 848900 1.13* 
(1.01, 
1.26) 1289724 1.11* 
(1.00, 
1.23) 1621452 
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Table 12: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Female Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
(refer-
ence) 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile'
s OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile'
s OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartil
e's OR 
N 
(Number 
of 
people 
used for 
the OR) 
Formaldehyde 
(27)   1.00 
1.42** (1.08, 1.87) 238691 1.23 
(0.98, 
1.55) 512801 1.34** 
(1.08, 
1.67) 720232 
Lead/ lead  
compounds 
(49)   1.00 
0.93 (0.81, 1.07) 891840 0.81* 
(0.71, 
0.93) 985396 1.15* 
(1.03, 
1.28) 1226351 
Manganese 
compounds 
(30)    1.00 
1.03 (0.87, 1.23) 919813 1.34*** 
(1.12, 
1.60) 662482 1.02 
(0.84, 
1.24) 515580 
Methanol (34)   1.00 1.13 
(0.96, 
1.34) 837831 1.08 
(0.91, 
1.28) 681676 1.07 
(0.90, 
1.28) 689674 
The measurements for toxicants and selected produced compounds were reported in pounds for the year 2002.                 
a 95% CI is calculated using the case-control study estimation model.                                                                                     
b Every county that had information concerning the respective variable was included.  The total number of counties in GA 
is 159 at the time of this study.                                                                                                                                                  
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables.                                               
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables.                                             
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables.                                          
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables. 
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Table 13 showed odds ratios tended to increase for male MS self-reported 
from the second to the fourth quartiles of county level emissions in pounds of outdoor 
air for recognized developmental toxicants, suspected endocrine toxicants, suspected 
immunotoxicants, suspected kidney toxicants, ammonia and formaldehyde.  It is 
important to note only the counties that reported values for the variable of interest 
were included for each variable.  
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Table 13: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Male Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Recognized 
Carcinogens 
(83)  
1.00 0.84 (0.69, 1.03) 1336736 0.97 
(0.81, 
1.15) 1971852 0.95 
(0.79, 
1.15) 1561433 
Suspected 
Carcinogens 
(63)   
1.00 1.19 (0.97, 1.47) 1371767 0.88 
(0.69, 
1.13) 1032001 1.31** 
(1.08, 
1.58) 2090183 
Suspected 
Cardio-
vascular or 
Blood 
Toxicants (99)   
1.00 1.25 (0.97, 1.61) 887363 1.08 
(0.85, 
1.36) 1475807 1.32* 
(1.06, 
1.64) 2386972 
Recognized 
Develop-
mental 
toxicants (79)   
1.00 0.95 (0.75, 1.20) 1177051 1.20 
(0.97, 
1.49) 1476386 1.25* 
(1.02, 
1.53) 1901945 
Suspected 
Develop-
mental 
toxicants (94)   
1.00 1.05 (0.83, 1.32) 1108782 0.90 
(0.72, 
1.11) 1528635 1.31** 
(1.09, 
1.59) 2179816 
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Table 13: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Male Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Suspected 
Endocrine 
toxicants (64)   
1.00 0.90 (0.72, 1.13) 1081817 0.93 
(0.76, 
1.12) 1523378 1.22* 
(1.02, 
1.46) 2042218 
Suspected 
Immuno-
toxicants (96)   
1.00 0.88 (0.70, 1.11) 1144129 0.99 
(0.81, 
1.21) 1581192 1.27** 
(1.06, 
1.52) 2345808 
Suspected 
Kidney 
toxicants (100)  
1.00 1.02 (0.79, 1.32) 979880 1.06 
(0.84, 
1.33) 1507946 1.33** 
(1.07, 
1.65) 2287042 
Suspected 
Gastro-
intestinal or 
liver toxicants 
(107)   
1.00 1.31* (1.03, 1.66) 1039370 1.01 
(0.80, 
1.27) 1538060 1.42*** 
(1.15, 
1.75) 2308938 
Suspected 
Muscoskeletal 
toxicants (32)   
1.00 1.21* (1.00, 1.47) 1288785 0.90 
(0.72, 
1.13) 1172223 1.22* 
(1.01, 
1.47) 1303313 
Suspected 
Neuro-
toxicants (104)  
1.00 0.97 (0.80, 1.19) 1380434 0.72** 
(0.58, 
0.90) 1288895 1.15 
(0.96, 
1.38) 2325153 
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Table 13: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Male Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
 
Recognized 
Reproductive 
toxicants (70) 
1.00 1.13 (0.90, 1.42) 1248814 0.96 
(0.74, 
1.24) 972226 1.44*** 
(1.18, 
1.76) 2117290 
Suspected 
Reproductive 
toxicants (103)  
1.00 1.40** (1.10, 1.79) 1120976 1.08 
(0.85, 
1.37) 1483292 1.51*** 
(1.22, 
1.87) 2326580 
Suspected 
Respiratory 
Toxicants 
(103)   
1.00 0.98 (0.78, 1.23) 1043921 0.86 
(0.70, 
1.06) 1605113 1.21* 
(1.01, 
1.45) 2359273 
Suspected 
Skin or Sense 
Toxicants 
(101)   
1.00 0.97 (0.78, 1.21) 1098398 0.80* 
(0.65, 
0.98) 1525415 1.16 
(0.97, 
1.39) 2342849 
Acetaldehyde 
(14)   
1.00 0.62 (0.29, 1.30) 138385 1.03 
(0.66, 
1.60) 333888 0.77 
(0.47, 
1.27) 251087 
Ammonia (39)   1.00 0.82 
(0.58, 
1.15) 835606 1.17 
(0.96, 
1.43) 1274741 1.16 
(0.97, 
1.39) 1574191 
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Table 13: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: County Level Emissions and Male Self-
Reported MS cases  
 Variable (# of 
counties in 
analysisb) 
OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of people 
used for 
the OR) 
OR for 
third 
quartile 
95% 
CIa of 
the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% 
CIa of 
the 
highest 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
Formaldehyde 
(27)   
1.00 1.90* (1.06, 3.43) 233543 1.86** 
(1.13, 
3.10) 486944 2.38*** 
(1.48, 
3.87) 690268 
Lead/ lead  
compounds 
(49)   
1.00 0.88 (0.67, 1.16) 886074 0.93 
(0.72, 
1.19) 962142 1.17 
(0.96, 
1.42) 1227852 
Manganese 
compounds 
(30)    
1.00 1.06 (0.77, 1.47) 900176 1.37 
(0.99, 
1.91) 651134 1.03 
(0.72, 
1.48) 494192 
 
Methanol (34) 
 
1.00 
 
1.12 
 
(0.83, 
1.51) 
 
804235 
 
1.20 
 
(0.88, 
1.63) 
 
653121 
 
1.04 
 
(0.76, 
1.42) 
 
646463 
The measurements for toxicants and selected produced compounds were reported in pounds for the year 2002.                   
a 95% CI is calculated using the case-control study estimation model.                                                                                      
b Every county that had information concerning the respective variable was included.  The total number of counties in GA 
is 159 at the time of this study.                                                                                                                                                   
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables.                                                
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables.                                               
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables.                                           
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables. 
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Table 14 shows increasing odds ratios for total MS self-reported cases with 
increasing emissions of selected criteria air pollutants to outdoor air for carbon 
monoxide (mobile sources), nitrogen oxides (mobile and areas sources), PM-2.5 
(mobile sources), PM-10 (mobile sources), and volatile organic compounds (mobile 
sources).  In addition, the odds ratios tended to increase from the second to the fourth 
quartile for nitrogen (all sources), PM-2.5 (area and all sources), PM-10 (area and all 
sources), sulfur dioxide (area and all sources), and volatile organic compounds (area 
sources).  The majority of these findings were highly statistically significant. 
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Table 14: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Total Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile 
OR  
N (Number 
of people 
used for 
the OR) 
Carbon 
Monoxide 
(mobile) 
1.00 1.21* (1.00, 1.47) 1067078 1.26* 
(1.11, 
1.42) 1546590 1.63****
(1.38, 
1.92) 6946275 
Carbon 
monoxide  
(area) 
1.00 1.29**** (1.15, 1.44) 2906874 1.26****
(1.12, 
1.42) 2366165 1.46****
(1.31, 
1.62) 5166698 
Carbon 
monoxide  
(all) 
1.00 0.75**** (0.65, 0.86) 1343172 0.72****
(0.64, 
0.82) 1915213 1.04 
(0.94, 
1.15) 6850832 
Nitrogen 
oxides  
(mobile) 
1.00 1.01 (0.85, 1.19) 1205793 1.04 
(0.89, 
1.21) 1596924 1.40****
(1.22, 
1.61) 6930996 
Nitrogen 
oxides  
(area) 
1.00 1.02 (0.90, 1.15) 1849188 1.09 
(0.97, 
1.22) 2364973 1.23****
(1.11, 
1.36) 6178314 
Nitrogen 
oxides 
(all) 
1.00 0.94 (0.79, 1.12) 1128444 0.94 
(0.80, 
1.11) 1702089 1.43****
(1.23, 
1.65) 6793742 
PM-2.5  
(mobile) 1.00 1.21 
(0.99, 
1.49) 993506 1.22* 
(1.00, 
1.48) 1510700 1.75****
(1.47, 
2.10) 6998801 
PM-2.5  1.00 0.94 (0.85, 2858242 1.01 (0.90, 2444023 1.16** (1.05, 5065518 
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Table 14: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Total Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile 
OR  
N (Number 
of people 
used for 
the OR) 
(area) 1.05) 1.12) 1.28) 
PM-2.5  
(all) 1.00 0.89 
(0.77, 
1.03) 1384414 1.00 
(0.88, 
1.13) 2425057 1.23*** 
(1.09, 
1.38) 6163914 
PM-10  
(mobile) 1.00 1.00 
(0.84, 
1.20) 1048779 1.06 
(0.90, 
1.25) 1740213 1.47****
(1.27, 
1.70) 6858117 
 
PM-10  
(area) 
 
1.00 
 
0.93 
 
(0.83, 
1.03) 
 
2475108
 
0.93 
 
(0.84, 
1.04) 
 
2493041
 
1.12* 
 
(1.02, 
1.24) 
 
5468954 
PM-10  
(all) 1.00 0.87 
(0.74, 
1.01) 1172668 0.87* 
(0.76, 
0.99) 2312006 1.20** 
(1.06, 
1.35) 6359593 
Sulfur 
dioxide   
(mobile) 
1.00 1.09 (0.91, 1.30) 1077110 0.95 
(0.81, 
1.13) 1598051 1.50****
(1.29, 
1.74) 6960012 
Sulfur 
dioxide   
(area) 
1.00 0.93 (0.79, 1.09) 1256009 0.94 
(0.81, 
1.09) 1728222 1.43****
(1.27, 
1.62) 6942742 
Sulfur 
dioxide   
(all) 
1.00 0.94 (0.79, 1.12) 1191739 1.15 
(0.98, 
1.34) 2034489 1.36****
(1.18, 
1.57) 6396515 
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Table 14: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Total Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile 
OR  
N (Number 
of people 
used for 
the OR) 
VOCs  
(mobile) 
1.00 1.09 (0.91, 1.30) 1087960 1.14 
(0.96, 
1.34) 1593661 1.48****
(1.27, 
1.72) 6939764 
VOCs 
(area) 
1.00 0.80* (0.68, 0.95) 1092424 0.94 
(0.81, 
1.09) 1727586 1.25*** 
(1.09, 
1.42) 6888893 
VOCs 
(all) 
1.00 1.10 (0.92, 1.33) 1087682 1.09 
(0.92, 
1.30) 1546984 1.54****
(1.32, 
1.80) 6962477 
Each variable under analysis included 158 of the 159 counties in GA.   VOCs are volatile organic compounds, and PM 
is particulate matter.    Also, the selected air pollutants were reported as emissions in tons, in 1999.                                
a 95% CI is calculated using the case-control study estimation model                                                                                  
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables                                           
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables                                          
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables                                       
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables 
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Table 15 shows increasing odds ratios for female MS self-reported cases with 
increasing emissions of selected criteria air pollutants to outdoor air for carbon 
monoxide (mobile and area sources), nitrogen oxides (areas sources), and PM-2.5 
(mobile sources).  In addition, the odds ratios tended to increase as we go from the 
second to the fourth quartile for nitrogen oxides (mobile and all sources), PM-2.5 
(area and all sources), PM-10 (mobile, area and all sources), sulfur dioxide (area and 
all sources), and volatile organic compounds (mobile and area sources).  The majority 
of the findings were highly statistically significant.   
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Table 15: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Female Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% 
CIa of 
the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N (Number 
of people 
used for 
the OR) 
Carbon 
Monoxide 
(mobile) 
1.00 1.13 (0.90, 1.41) 535442 1.23 
(0.99, 
1.51) 776385 1.55****
(1.28, 
1.88) 3515655 
Carbon 
monoxide  
(area) 
1.00 1.26*** (1.10, 1.44) 1478302
 
1.27*** 
(1.10, 
1.46) 1192659 1.44****
(1.27, 
1.63) 2604139 
Carbon 
monoxide  
(all) 
1.00 0.76*** (0.64, 0.89) 676178 0.72****
(0.62, 
0.83) 965122 1.04 
(0.92, 
1.17) 3469210 
Nitrogen 
oxides  
(mobile) 
1.00 0.98 (0.81, 1.19) 604846 1.01 
(0.84, 
1.21) 803584 1.34*** 
(1.15, 
1.58) 3508701 
Nitrogen 
oxides  
(area) 
1.00 1.02 (0.88, 1.18) 931641 1.08 
(0.95, 
1.24) 1198135 1.23*** 
(1.10, 
1.39) 3128221 
Nitrogen 
oxides 
(all) 
1.00 0.87 (0.71, 1.07) 565409 0.90 
(0.75, 
1.09) 858482 1.35*** 
(1.14, 
1.60) 3439471 
PM-2.5  
(mobile) 
1.00 1.13 (0.88, 1.44) 498241 1.19 
(0.95, 
1.49) 760421 1.68****
(1.37, 
2.07) 3543774 
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Table 15: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Female Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% 
CIa of 
the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N (Number 
of people 
used for 
the OR) 
PM-2.5  
(area) 
1.00 0.90 (0.80, 1.03) 1453576 1.02 
(0.90, 
1.16) 1233432 1.14* 
(1.02, 
1.28) 2550552 
PM-2.5  
(all) 
1.00 0.84* (0.71, 1.00) 695928 0.95 
(0.82, 
1.10) 1229098 1.18* 
(1.03, 
1.34) 3114398 
PM-10  
(mobile) 
1.00 0.97 (0.78, 1.20) 527312 1.07 
(0.89, 
1.30) 878612 1.46****
(1.23, 
1.74) 3469741 
PM-10  
(area) 
1.00 0.90 (0.79, 1.02) 1256057 0.95 
(0.84, 
1.08) 1257146 1.12* 
(1.00, 
1.25) 2758341 
PM-10  
(all) 
1.00 0.89 (0.74, 1.07) 588260 0.88 
(0.76, 
1.04) 1172605 1.23** 
(1.06, 
1.42) 3211310 
Sulfur 
dioxide   
(mobile) 
1.00 1.06 (0.87, 1.33) 542359 0.95 
(0.77, 
1.16) 800885 1.48****
(1.24, 
1.77) 3521391 
Sulfur 
dioxide   
(area) 
1.00 0.95 (0.79, 1.16) 633212 1.00 
(0.84, 
1.19) 870761 1.47****
(1.26, 
1.70) 3518047 
Sulfur 
dioxide   
(all) 
1.00 0.93 (0.76, 1.15) 597066 1.10 
(0.92, 
1.32) 1027098 1.31** 
(1.11, 
1.56) 3238501 
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Table 15: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Female Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% 
CIa of 
the 
second 
quartile 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N (Number 
of people 
used for 
the OR) 
VOCs  
(mobile) 
1.00 1.00 (0.81, 1.24) 546468 1.10 
(0.90, 
1.34) 797603 1.41****
(1.19, 
1.69) 3514205 
VOCs 
(area) 
1.00 0.84 (0.69, 1.03) 549203 0.97 
(0.81, 
1.16) 868446 1.28** 
(1.09, 
1.49) 3489057 
VOCs 
(all) 
1.00 1.12 (0.90, 1.40) 545179 1.10 
(0.89, 
1.35) 779424 1.56****
(1.29, 
1.88) 3524818 
Each variable under analysis included 158 of the 159 counties in GA.   VOCs are volatile organic compounds, and PM 
is particulate matter.    Also, the selected air pollutants were reported as emissions in tons, in 1999.                                 
a 95% CI is calculated using the case-control study estimation model                                                                                 
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables                                            
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables                                          
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables                                       
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables 
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Table 16 shows increasing odds ratios for male MS self-reported cases with 
increasing emissions of selected criteria air pollutants to outdoor air for PM-2.5 (all 
sources), sulfur dioxide (all sources), and volatile organic compounds (all sources).  
In addition, the odds ratios tended to increase from the second to the fourth quartile 
for nitrogen oxides (mobile and areas sources) and volatile organic compounds (area 
sources). 
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Table 16: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Male Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile's 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N (Number 
of people 
used for 
the OR) 
Carbon 
Monoxide 
(mobile) 
1.00 1.51 (0.98, 2.35) 531636 1.45 
(0.96, 
2.20) 770204 1.93*** 
(1.32, 
2.85) 3430620 
Carbon 
monoxide  
(area) 
1.00 1.37* (1.07, 1.75) 1428572 1.21 
(0.93, 
1.56) 1173506 1.51*** 
(1.21, 
1.91) 2562559 
Carbon 
monoxide  
(all) 
1.00 0.76 (0.56, 1.03) 666994 0.73* 
(0.56, 
0.96) 950091 1.07 
(0.86, 
1.33) 3381622 
Nitrogen 
oxides   
(mobile) 
1.00 0.94 (0.65, 1.36) 600947 1.10 
(0.79, 
1.55) 793340 1.47** 
(1.09, 
1.99) 3422295 
Nitrogen 
oxides   
(area) 
1.00 0.99 (0.76, 1.29) 917547 1.09 
(0.85, 
1.39) 1166838 1.24* 
(1.00, 
1.54) 3050093 
Nitrogen 
oxides   
(all) 
1.00 1.15 (0.77, 1.74) 563035 1.14 
(0.78, 
1.67) 843607 1.74*** 
(1.23, 
2.46) 3354271 
PM-2.5   
(mobile) 
1.00 1.28 (0.82, 2.02) 495265 1.24 
(0.81, 
1.90) 750279 1.84** 
(1.25, 
2.73) 3455027 
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Table 16: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Male Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile's 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N (Number 
of people 
used for 
the OR) 
PM-2.5   
(area) 
1.00 1.04 (0.83, 1.32) 1404666 0.96 
(0.75, 
1.22) 1210591 1.24* 
(1.00, 
1.54) 2514966 
PM-2.5   
(all ) 
1.00 1.16 (0.84, 1.61) 688486 1.22 
(0.91, 
1.63) 1195959 1.51** 
(1.16, 
1.98) 3049516 
PM-10   
(mobile) 
1.00 0.96 (0.65, 1.41) 521467 0.95 
(0.719, 
1.248) 861601 1.415* 
(1.121, 
1.785) 3388376 
PM-10   
(area) 
1.00 1.04 (0.83, 1.32) 1219051 0.92 
(0.72, 
1.16) 1235895 1.18 
(0.96, 
1.45) 2710613 
PM-10   
(all) 1.00 0.88 
(0.63, 
1.22) 584408 0.86 
(0.65, 
1.13) 1139401 1.18 
(0.92, 
1.53) 3148283 
Sulfur 
Dioxide   
(mobile) 
1.00 1.23 (0.83, 1.85) 534750 1.13 
(0.77, 
1.65) 797166 1.72** 
(1.22, 
2.42) 3438621 
Sulfur 
Dioxide   
(area) 
1.00 0.81 (0.58, 1.13) 622797 0.74 
(0.54, 
1.00) 857461 1.29* 
(1.00, 
1.66) 3424695 
Sulfur 
Dioxide   
(all) 
1.00 1.05 (0.71, 1.55) 594673 1.32 
(0.93, 
1.88) 1007391 1.56** 
(1.12, 
2.18) 3158014 
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Table 16: Odds Ratios(OR) and 95% Confidence Interval (CI) by Quartile: Criteria Air Pollutants and Male Self-
Reported MS cases 
 Variable OR for 
lowest 
quartile 
OR for 
second 
quartile 
95% CIa 
of the 
second 
quartile's 
OR 
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
third 
quartile 
95% CIa 
of the 
third 
quartile's 
OR  
N 
(Number 
of 
people 
used for 
the OR) 
OR for 
highest 
quartile 
95% CIa 
of the 
fourth 
quartile's 
OR  
N (Number 
of people 
used for 
the OR) 
VOCs   
(mobile) 
1.00 1.51* (1.00, 2.27) 541492 1.35 
(0.92, 
1.99) 796058 1.79*** 
(1.26, 
2.56) 3425559 
VOCs   
(area) 
1.00 0.68* (0.48, 0.98) 543221 0.82 
(0.60, 
1.11) 859140 1.14 
(0.87, 
1.49) 3399836 
VOCs   
(all) 
1.00 1.03 (0.69, 1.53) 542503 1.10 
(0.76, 
1.59) 767560 1.51* 
(1.09, 
2.11) 3437659 
Each variable under analysis included 158 of the 159 counties in GA.   VOCs are volatile organic compounds, and PM 
is particulate matter.    Also, the selected air pollutants were reported as emissions in tons, in 1999.                                  
a 95% CI is calculated using the case-control study estimation model                                                                                   
*Values are significant at the 0.05 level using a Chi-squared test for 2 x 2 contingency tables                                             
**Values are significant at the 0.01 level using a Chi-squared test for 2 x 2 contingency tables                                            
***Values are significant at the 0.001 level using a Chi-squared test for 2 x 2 contingency tables                                        
****Values are significant at the 0.0001 level using a Chi-squared test for 2 x 2 contingency tables 
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V.  Discussion and Conclusions 
Summary of Figures and Tables 
Again, the purpose of this research was to determine the distribution of MS in GA and 
also to examine the potential relationships between environmental air pollutants and the 
distribution of MS in GA.   From the geographic distribution of MS, we observed the bulk of the 
total and female self-reported MS prevalence rates seem to center around Atlanta, the largest city 
in GA. Also, we found the best predictive model for females with MS includes both per-capita 
income, a characteristic seen in studies done by Mayer and others (Mayer 1981), and PM-10.  
Males only had per-capita income in their predictive model.   In addition, per-capita income 
seemed to have a positive influence on the total and female rates in the model, while the PM-10 
seemed to have a negative influence on these rates in the model.   It is important to note this 
multivariate model only included U.S. census and NEI source emissions data, not TRI source 
emissions data, because NEI had data for 158 of 159 GA counties.  The TRI included data for 
between 32 and 107 counties, because emissions (total, to specific environmental media, and in 
processes or waste transported off site) must only be reported by sources to U.S. EPA over 
certain threshold levels.  If nothing in a county emitted enough to be required to report a specific 
pollutant to TRI, then that county did not have any information on that specific pollutant.   
The odds ratios (ORs) of all three population strata (total, female, and male) increased 
consistently with increases in the total population, male population, and per capita income.  Non-
consistent increases were observed for source emissions of developmental toxicants, suspected 
endocrine toxicants, suspected immunotoxicants, and suspected kidney toxicants.  The three 
population strata had lower ORs for people living in the same house in subsequent census 
collection years.   
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 For source emissions of criteria air pollutants, the ORs for total and female rates 
increased with increases of carbon monoxide (mobile sources), nitrogen oxides (areas sources), 
PM-2.5 (mobile sources), PM-10 (mobile sources), and volatile organic compounds (mobile 
sources).  In addition, the ORs increased as we go from the second to the fourth quartile for 
nitrogen (all sources), PM-2.5 (area and all sources), PM-10 (area and all sources), sulfur dioxide 
(area and all sources), and volatile organic compounds (area sources).  Also, male ORs increased 
with increasing emissions of PM-2.5 (all sources), sulfur dioxide (all sources), and volatile 
organic compounds (all sources).  Furthermore, the ORs increased from the second to the fourth 
quartile for nitrogen oxides (mobile and areas sources) and volatile organic compounds (area 
sources).   
Lastly, table 8 showed the percent black and percent white show significantly strong but 
varying ORs.  U.S. Census data does not differentiate Hispanics from the percent black or 
percent white groups, thus this may partially explain the large jumps in ORs.  This may support 
the need for Census data with percent white and percent black that do not include Hispanic 
populations.   
Discussion 
Prevalence rates help to control for differences in population distribution.  Thus, because 
of the greater prevalence of MS around the largest metropolitan statistical area in GA, Atlanta, 
and the increasing MS ORs when organized by people per square mile, this study’s results 
suggested a possible role of urban environmental factors in the MS distribution in GA.  This 
coincides with previous studies that suggested that MS rates were positively correlated with per 
capita income, physicians per capita, steel consumption, and several other characteristics which 
may increase in cities (Mayer 1981) as well as increased air pollution and other environmental 
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factors (Oikonen et al, 2003).  While this relationship was somewhat weak for the self-reported 
male prevalence rates, it was stronger for the female prevalence rates.  
These differences in the distribution and the models used could be due to several reasons.  
The majority of MS cases in GA were female.  This study has a female to male self-reported case 
ratio of  3.20 similar to studies conducted by Keegan et al. (2002) and Williamson et al. 
(Williamson 2007).  Thus, in the NMSS-GA data, females were more likely to self-report being 
diagnosed with MS, females were more likely to become a member, or a combination of both of 
these characteristics.   Thus, the prevalence in females will include a greater number of cases, 
and thus there may be less internal error in the female prevalence rates than in the male 
prevalence rates.  This could lead to more significant statistics for the females than for the males.  
Also, there were biochemical gender difference in the mouse model for MS (Spach and Hayes 
2005), thus there may also be biochemical gender differences between human MS patients.  In 
addition, while per-capita income has been seen in some studies as associated with MS (Mayer 
1981, Catanzaro et al 1992), PM-10 has never before been shown to be associated with MS 
prevalence rates; however, PM-10 has been shown to be associated with MS relapse in one study 
conducted in Finland (Oikonen et al. 2003).   
Our present study found that self-reported MS prevalence from the National Multiple 
Sclerosis Society’s Georgia Chapter (NMSS-GA) is also related strongly to PM-10 and MS may 
be positively associated with developmental toxicants, suspected endocrine toxicants, suspected 
immunotoxicants, suspected kidney toxicants, carbon monoxide (mobile sources), nitrogen 
oxides (areas and all sources), PM-2.5 (mobile, area, and all sources), PM-10 (mobile, are and all 
sources), and sulfur dioxide (area and all sources), and volatile organic compounds (area 
sources).   
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Biochemically, inhaled particulates like PM-10 can affect a number of host defenses, 
including the development of specific immune responses such as cell-mediated immunity, the 
principal part of the immune system implicated in MS.  Also, immune stimulation by particulates 
has also led to increased T-cell activity and immunoglobulin E (IgE) formation.  (Bom 2007)   
There is a clear relationship, based on many studies published over recent decades, 
between PM-10 and cardiovascular deaths and respiratory morbidity like asthma symptoms with 
measured increased outdoor air concentrations of PM-10.  Thus, PM-10 may affect not only the 
cardiovascular and respiratory systems, but also the immune system.  Furthermore the immune 
stimulation and IgE formation could lead to inflammation that is found in MS patients.   
In addition to the inflammatory role of PM-10 in MS, heavy metals in particulate matter 
have been believed to have a relationship with MS clusters (Ingalls 1986; Landrigan et al. 1975).  
Using odds ratios, we found a significant relationship between lead compounds and female or 
total MS rates, although this relationship was not seen with males.  Nevertheless, this study 
showed a stronger relationship with particulate matter than the relationship with heavy metals.   
The implications of this research are far-reaching.  Self-reported MS prevalence was 
highly associated with PM-10, at the county level, and PM-10 and per-capita income are best 
associated with MS in our model.  Still, the research of environmental air pollutants and MS is 
sparse, thus additional research is needed to confirm this and the previous study (Oikonen et al. 
2003) with richer outcome and exposure data.  
Advantages of This Study’s Methods 
This study was conducted using county level data for several reasons.  First, county level 
data allowed a more intense study of how regional emissions may be associated with regional 
rates of disease.  Also, county level data may allow this study to be repeated in states with 
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similar data.  State emissions data may prove difficult to compare to this study because the 
distribution of emissions are too large to ensure comparability; however, county level emissions 
may be specific enough to accomplish this comparison.  For example, previous research 
suggested different latitudes (Mayer 1981; Rosati 2001) made it difficult to compare data with 
other states further north or south.  This study’s methodology therefore helped ensure we could 
compare data from one county to another, instead of comparing GA data with states that have 
higher or lower MS prevalence because of the effect of sunlight.  While this study may have 
been done at an even smaller level, it was kept at the county level to help ensure continued 
confidentiality of members of the NMSS-GA.  
Also, this study was done using the NMSS-GA member list.  To date, a nationwide 
(beyond NMSS) MS registry has not been created; thus, these data may be from the most 
accurate database available throughout the country.   The NMSS-GA data are also a good source 
of data, because it is from a national database, and thus the information may be comparable to 
other NMSS chapter databases throughout the country.   
Limitations of This Study’s Methods  
There are several limitations to this study.  First of all, the cases are self-reported from 
the member’s list of the NMSS.  While cases were asked to write the date of their MS diagnosis, 
this information could be fabricated.  In addition, there is a small fee to register for the NMSS 
list.  Therefore there is a strong possibility there may be under-reporting and non-differential bias 
due to information error in our results.  Along with these limitations, there may also be relatively 
more underreporting in males, given generally males are less likely to seek medical care.  Still, 
the NMSS-GA estimated that its list included approximately 75% of the total MS cases in GA.   
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Also, these data are cross-sectional, although they represented a cumulative prevalence of 
self-reported MS cases in GA.  Therefore, only an estimate of true risk (OR) can be use, and 
casual inferences cannot be made. Georgia may have different laws, demographics, and other 
differences from other states.  Thus, because this study uses data from GA only, the analyses 
were interpreted as restricted to GA. There is the possibility these values may be comparable to 
states with a similar latitude as GA, although different exposure patterns and different 
environmental laws may make inter-state comparison difficult.  Also, birth years of the members 
were not received, thus this study could not correct for the potential confounding of age.  Lastly, 
using the remaining county population as controls for this study may not be the most robust 
method for obtaining controls.   A better method would be to use those who are also registered as 
family members of the members of the NMSS-GA, who may be at a higher genetic risk for MS.   
Conclusions and Recommendations for Future Research and Policy 
 There may be a role of environmental air pollutants in the start and progression of 
Multiple Sclerosis (MS).   In this study, the best model for predicting the female and total 
prevalence of MS in GA included both the per-capita income and coarse particulate matter (PM-
10).  PM-10 along with other environmental air pollutants had highly significant associations 
with the MS rates in GA, along with evidence of a possible dose response.   Moreover, a 
potential biochemical mechanism does exist.  While we do not know the true effects of 
environmental air pollutants through this study or others, we should explore PM-10 and other air 
pollutants people are widely exposed to.  
It is important to note the exact details of the biochemical mechanism that leads to MS is 
not currently known.  Thus, further study is warranted and desperately needed.  Future research 
should be done using the reported dates of diagnosis, to be able to assess yearly incidence as well 
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as prevalence.  Then, relative risk could be calculated as a true measure of risk, and not OR, 
which is only an estimate.  Also, including the month and year of birth in subsequent studies will 
facilitate eliminating the ever-present confounding of age.  Also, collecting ethnicity-data would 
be beneficial, because MS has been more common among some races than others (Keegan and 
Noseworthy 2002; Rosati 2001).  This will allow future research to also control for racial 
differences.  Lastly, more robust studies, such as prospective studies that are nested in the past, 
using various data available, may help provide more robust data for further analysis.   
From a policy point of view, a MS registry is desperately needed.  While we do have self-
reported data that may be somewhat accurate, a universal definition and universal data collection 
would help scientists solidify the epidemiology of MS and conclusions from these studies.   This 
registry must include important demographic information such as date of birth, race, date of 
diagnosis by a physician, and county and state of residence.  Without a registry, MS data may 
continue to be underreported.  Also, MS research has been supported, and should continue to be 
supported across the world.  This disease has been known for a long time, yet, there is not a 
concrete list of causal factors.  More research may help to bring light and consensus among the 
many factors that may influence the start and progression of MS, as well as how many people are 
diagnosed with MS and the common and diverse exposures that they may have. 
 The distribution and determinants of disease is the foundation of epidemiology.  County-
level, or lower, graphic representations of MS are important.  While MS may seem to be equally 
distributed throughout the state, it was not in this study.  Through finding high-risk counties and 
determining their differences from low-risk counties, we may be able to gather further crucial 
information about MS.  
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 As it has for hundreds of years, the question of nature versus nurture rages on. This 
debate centers on whether genetics or our environment leads more directly to our behaviors and 
to our diseases.  It seems that MS may be a point of synthesis, for it embodies strong genetic and 
environmental factors.  May we work quickly to elucidate this relationship in MS, for lives 
depend upon it.
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Appendix A.  Selected Variables and Correlations with Multiple Sclerosis Prevalence (caption 
shows “Table 3”) (Mayer 1981) 
 
Many different factors like mean annual house of sunshine, mean annual temperature and infant 
mortality were found to be protective of Multiple Sclerosis.  Contrarily steel consumption, 
number of physicians per capita, literacy rate, latitude from equator, gross energy consumption, 
gross national product per capita and food consumption were all associated with higher rates of 
MS   
(Mayer 1981) 
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Appendix B: Figures 1, 2 and 3 (Rosati 2001) 
 
Figures 1, 2 and 3 show Geographical Information Systems maps of Multiple Sclerosis 
prevalence (per 100,000) in the United States, Africa and around the United Kingdom, 
respectively.   (Rosati 2001) 
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In all three of these Geographic Information System (GIS) models, Rosati et al. show that there 
are significant geographical influences that may influence the rate of MS in several countries.  
(Rosati 2001) 
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Appendix C: Crude and adjusted odds ratios (95% Confidence Intervals) for mortality from 
Multiple Sclerosis associated with indicators of exposure to sunlight and socioeconomic status, 
USA, 1984-1985  (Freedman et al. 2000) 
Appendix 3   Crude and adjusted ORs (95% CIs) for mortality from Multiple Sclerosis 
associated with indicators of exposure to sunlight and socioeconomic status, USA, 1984-
95 
  Multiple Sclerosis Skin cancer  
  Crude Adjusted* Crude Adjusted 
Residential Sunlight 
  Low 1 1 1 1
  Moderate 0.58 (0.54 to 
0.62) 
0.59 (0.55 to 
0.63) 
1.12 (1.04 to 
1.20) 
1.15 (1.07 to 
1.23)  
  High 0.55 (0.51 to 
0.59) 
0.53 (0.48 to 
0.57) 
1.15 (1.07 to 
1.24) 
1.24 (1.15 to 
1.35)  
Occupational  
  Indoor 1 1 1 1
  Mixed 0.87 (0.77 to 
0.97) 
0.89 (0.78 to 
1.02) 
1.30 (1.19 to 
1.42) 
1.03 (0.93 to 
1.14)  
  Outdoor 0.40 (0.33 to 
0.47) 
0.74 (0.61 to 
0.89) 
1.53 (1.40 to 
1.68) 
1.21 (1.09 to 
1.34)  
Socioeconomic status:  
  1 Low 1 1 1 1
  2 1.36 (1.19 to 
1.55) 
1.00 (0.88 to 
1.15) 
0.92 (0.84 to 
1.0) 
0.93 (0.85 to 
1.01)  
  3 2.45 (2.19 to 
2.75) 
1.90 (1.68 to 
2.13) 
0.90 (0.83 to 
0.97) 
0.89 (0.82 to 
0.96)  
  4 3.08 (2.73 to 
3.49) 
2.26 (1.99 to 
2.57) 
0.87 (0.79 to 
0.95) 
0.90 (0.82 to 
1.00)  
  5 High 
 
3.39 (2.89 to 
3.99) 
3.07 (2.59 to 
3.62) 
1.19 (1.04 to 
1.36) 
1.07 (0.94 to 
1.23) 
* Adjusted ORs were calculated with logistic regression, adjusting for age, sex, race and 
socioeconomic status, except in the case of socioeconomic status where adjustments 
were for age, sex and race. 
Residence sunlight was defined as residing in a region both at birth and at the time of 
death. Regions are defined in Appendix 1. Subjects who resided in different regions at 
birth and at the time of death were excluded. 
Occupational analysis was limited to those subjects whose usual occupation was 
classified as highly or moderately active to exclude those whose indoor jobs reflected 
restricted job options due to the disabilities of their disease. Homemakers were also 
excluded.  
Freedman et al. show that residential sunlight is protective of MS (OR=0.53).  They also show 
state that under the highest sun exposure white men, white women, black men and black women 
(adjusted OR=0.57, 0.49, 0.44, 0.59, respectively[data not shown]) have similar rates.  
(Freedman et al. 2000)  
